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ABSTRACT 
Nitric oxide syTlthase (NOS), a cytochrome P450-like oxygenase, catalyzes nitric 
oxide (NO) production in a two cycle reaction: the first step leads to the production of 
N-hydroxy-L-arginine (NOHA), the stable enzyme-bound intermediate, while the 
second cycle results in the production of NO and L-citrulline. The three mammalian 
isozymes are homodimeric enzymes and each monomer is composed of a reductase 
and an oxygenase domain. The oxygenase domain contains the arginine binding site 
and needs one heme (protoporphyrin LX) ligated by a cysteine thiolate, and one I-LB 
molecule. Enzyme substrates are 02, L-argimne (or NOHA) and NADPH, which 
provides electrons for the activation of oxygen. H4B is an essential cofactor for NO 
production by NOS and its roles are in dimerization and as an electron 
donor/acceptor. In each cycle the generally accepted reaction sequence that involves 
the heme iron is: 
e 	 02 	 2H 
Fe(III) 'Fe(I)_ Fe(II)-O2 v'- 	,.(Fe(II)-0--*Fe(III)-O2'i 	 Fe(IV)O 
H20 
the first electron is transferred from the reductase domain, and the second electron 
donated by H413. Amino acid residues in the distal portion of NOS heme domain are 
involved in the stabilization and activation of the oxygen-heme complexes formed 
during NO production. An amino acid residue with the ability of forming hydrogen-
bonds at a suitable distance from the space where substrate and oxygen-heme 
complexes interact may introduce species stabilization during the course of oxygen 
activation. With this in mind a mutant of nNOS,,x y  was generated where glycine 586 
was replaced by a serine residue (G586S nNOS0). It was then expressed and purified 
as the truncated heme domain and spectroscopic (UV-Vis) characterization of the 
mutant to verify that it retained its structural integrity was performed. The way the 
mutation affects the binding of a variety of compounds, such as substrates, substrate- 
analogues and diatomic ligands, was tested and compared with that characterizing the 
wild type. 
Stopped Flow experiments monitoring Oxy-Ferrous compound formation and decay 
were performed and analyzed in a comparison with the wild type nNOS 0,,. We report 
the formation of a novel reaction intermediate during G5865 nNOS0 reaction in the 
presence of I-LB and substrate, subsequent to the formation of the Oxy-Ferrous 
compound. The nature of the newly detected species has been investigated repeating 
stopped flow experiments in a variety of conditions, such as the absence of substrate 
and replacing 144B with amino-11413, a strong inhibitor of NOS activity. The fact that 
the new intermediate was not detected when substrate-bound G586S nNOS 0 reacts 
in the presence of amino-RjB, points to how its formation relies on the second 
electron being donated to the oxy-ferrous compound (from H 413). In order to assess 
whether the mutation affects the reduction potential of the G586S mutant, 
potentiometric titrations were conducted in the presence and absence of the substrate, 
evidencing that the mutant enzyme retains the heme native electrical properties. 
Finally crystals of the G586S mutant with L-arginine bound in the catalytic site were 
grown and the X-Ray structure solved. This showed that the newly introduced serine 
586 is at a suitable distance from the substrate guanidinium group to form a hydrogen-
bond: this causes a repositioning of the substrate itself, which in turn justifies the 















A Ala Methionine M Met 
C Cys Asparagine N Asn 
D Asp Proline P Pro 
E Glu Glutamine Q Gin 
F Phe Arginine R Arg 
G Gly Serine S Ser 
H His Threonine T Thr 
I He Valine V Val 
K Lys Ttyptophan W Trp 
L Leu Tyrosine Y Tyr 
Standard Units 
in Metre °C 	Celsius 
A Angstrom 1 	Litre 
g Gram V 	Volt 
s Second M 	Molar 
Kinetic Parameters 
Maximal turnover rate constant 
KM 	Michaelis constant 
K4j 	 Dissociation constant 
Observed rate constant at saturating concentrations of substrate 
vi' 
k Rate constant for first-electron transfer 
Rate constant for second-electron transfer 
kautox Rate constant for oxy-ferrous decay 
k0b Observed rate constant 





cGMP Cyclic guanosine monophosphate 
cNOS Constitutive NOS 
CYP Cytochrome P450 
Da Dalton 
dH20 Deionised water 
DMSO Dimethyl Sulfoxide 
cx Extinction coefficient at wavelength x nm 
E. coli Escherichia coli 
EDRF Endothelium-derived relaxing factor 
EDTA Ethylenediaminetetraacetic acid 
E. Midpoint potential 
eNOS Endothelial NOS 
EPR Electron Paramagnetic Resonance 
vii' 
FAD Flavin Adenine Dinucleotide 
FMN Flavin Mononucleotide 
11413 Tetrahydrobiopbterin 
hd Heme Domain 
iNOS inducible NOS 
NADH -Nicotinamide adenine dinucleotide 
NAME N-Nitro-L-Arginine Methyl Ester 
NIO N-iminoethyl-L-ornithine 
NADPH 13-Nicotinamide adenine dinucleotide phosphate 
nNOS neuronal NOS 
NO Nitric oxide 
NOHA N-Hydroxy-arginine 
NOS Nitric Oxide Synthase 
NOSOXy NOS oxygenase domain 
OTI'LE Optically Transparent Thin Layer Electrode 
ox Oxidised 
P450 BM3 Cytochrome P450 monooxygenase from Bacillus megaterium 
P450 cam Cytochrme P450 monooxygenase from Pseudomonas putida 
PDB Protein data bank 
red Reduced 
SDS-PAGE Sodium dodecylsulphate-polyacrylanflde gel electrophoresis 
SHE Standard hydrogen electrode 
RMSD Root mean square deviation 
Iris Tris(hydroxyl)aminomethane 
UV Ultra Violet 
ix 
vis 	 visible 
WT 	 Wild type 
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1 INTRODUCTION 
1.1 Nitric Oxide 
Nitric oxide (NO) is a signalling molecule that is involved in a multiplicity of 
physiological processes: in fact the number of pathways in which it plays a role is 
growing rapidly since the first discovery of its role as a vascular tone regulator. Its 
tasks range from cytotoxic agent during immune response, to neurotransmitter 
diffusing between synapses. Its versatility is due to its size, reactivity and absence of 
charge, among others. The capability to diffuse across hundreds of microns and to 
form complexes with transition metals explain why NO is such an eclectic factor and 
why it acts as a mediator for such a large number of targets belonging to cascades 
with both eventual protective and destructive effects. On the other hand it is quite 
surprising to find that a molecule, which is commonly known as a very unstable air 
pollutant, is central to so many biological processes. 
The importance of NO as a topic of research arose when, in 1986, it was identified as 
the previously called endothelium-derived relaxing factor (EDRF) by two groups 
researching independently (1,2). New evidence for its involvement in pathologies 
have been detected since that moment with an impressive pace. The following 
examples of NO implication are just a tiny selection to represent its ubiquity. 
Nitrosylation is a protein post-translation modification analogous to phosphorylation 
that can modify the activity of a protein (3). The most known nitrosylation, although 
not the only possible, is S-nitrosylation. This is the reaction of NO with certain 
cysteine residues in a protein. Targets of this modification can be proteins with an 
essential role in an organism such as haemoglobin (4) and serum albumin (5). 
2 
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Malfunctioning protein nitrosylation, and obviously its reverse reaction, 
denitrosylation, have been associated with pathologies such as myocardial ischemia, 
atherosclerosis, inflammation, and cancer. 
One of the most important enzymes targeted by the action of NO is the soluble 
Guanylyl Cyclase, the enzyme that converts guanosine triphosphate (GTP) into cyclic 
guanosine monophosphate (cGMP). The importance of this interaction derives from 
the huge number of processes in which cGMIP has a role: among others it acts as an 
effector of smooth muscle relaxation, regulator of synaptic transmission and platelet 
aggregation inhibitor (6,7). These and other processes are modulated through the 
action of cGMP-dependent enzymes, such as protein kinases, phosphodiesterases and 
ion channels. NO react with guanylyl cyclase by binding to its prosthetic heme group 
enhancing cGMP production by up to 400-fold. In fact, as NO production is sensitive 
to the increase of calcium concentration, it is basically the linking step between the 
entrance of calcium into the cytoplasm and the production of cGMP and all the 
effects due to it (figure 1.1). 
3 












Figure 1.1: Diagram illustrating the cascade of events that connect the entrance of 
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1.1.1 Physical and chemical properties of Nitric Oxide 
NO is a colourless gas which turns blue on condensing to the liquid phase (8). The 
electronic configuration of NO is (t)2 (*)2  (it 
,(,),)4 ( )2 
(it 
,)1 and the Molecular 
Orbital energy level diagram is shown in figure 1.2. 
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Figure 1.2: Molecular-orbital energy-level diagram for nitric oxide. 
The last unpaired electron takes position in a it' orbital, this is responsible for the 
main physical and chemical features of NO. The bond order equals 2.5 and suggests 
that NO is less stable than NO (nitrosyl cation), which has a bond order of 3 and a 
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shorter bond length (1.06 A compared to 1.15 A). The ionization energy of the 
reaction NO—NO is, as expected, much lower than that for N 2–N2: this is 
consistent with the fact that the odd electron is positioned in an antibonding orbital 
and is shielded from the nucleus by the inner electrons. When complexed with metals, 
NO can be considered to be either an electron donor or acceptor, binding as either 
NO in a linear geometry or as N0 in a bent geometry, both via the nitrogen. The 
most common metal-nitrosyl complexes are with Fe, Ru and Ni. The small difference 
in electronegativity between oxygen and nitrogen gives the bond a tiny polar 
character, with the electrons being more probably found around the oxygen atom. 
Nevertheless NO could be described as an almost non polar molecule. 
31 
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1.1.2 Biological NO synthesis 
Nitric oxide in organisms is enzymatically produced by means of the reaction 
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L-Arginine 	N°-Hydroxy-L-Arginme 	L-Citrulline 
Figure 1.3: Enzyme catalyzed production of NO. 
L-Arginine, once bound into the catalytic site, can undergo a first oxidation, that, with 
the consumption of molecular oxygen and 2 electrons, leads to the formation of N-
Hydroxy-L-Arginine (NOHA). This reaction intermediate stays bound to the catalytic 
site and undergoes a second reaction, which is performed with the consumption of 1 
electron equivalent and 1 molecule of oxygen. This leads to the production of L-
Citrulline and nitric oxide. Both steps of the reaction require the reductive activation 
of an oxygen molecule. The reaction requires the presence of a number of cofactors 
and conditions; these will be described and analyzed in the catalytic cycle chapter. 
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1.2 Nitric Oxide Synthase 
The group of enzymes that produce nitric oxide in eukaryotes and in some 
prokaryotes are called Nitric Oxide Synthases (10). The mammalian NOSs are big 
dimenc proteins in which each monomer is made of two domains, with a specific 
connecting region between the two (figure 1.4). 
Bacterial NOS 	N-f hems i-c 
Inducible NOS 	N-f home ]—lCaM-{FMH HFADWADPIII_c 
Endothelial NOS 	N-f home J-FaMI-I IIoonh1MHDNADPHI4C 
Neuronal NOS N-IiflhJ--f hems I-ka*I II0OPIFMNIPADNADP11UC-o!k 
Figure 1.4: Modular composition of the different NOS isoforms, according to protein 
sequence. In red is the heme domain while the reductase domain is in yellow/green. 
The connecting portion is composed of a CaM binding region (orange). There is a 
loop (white) within the FMN domain of endothelial and inducible NOSs and a C-
terminal extension to both. Neuronal NOS is the only one having a PDZ-binding 
domain. The bacterial NOS consists of a heme domain, and requires an electron-
providing partner. Only the two constitutive NOSs have a C-terminal regulatory 
extension (dark yellow). 
The N-terminal domain is called the oxygenase or heme domain and binds the 
prosthetic group heme, the substrate L-arginine, the cofactor (6R)-5,6,7,8-
Tetrahydrobiopterin (H413) and is the portion of the protein where the actual 
production of NO happens. The C-terminal portion is called the reductase domain and 
has the function of providing electrons to the heme domain through the bound 
8 
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cofactors NADPH, FAD and FMN (figure 1.5). The connecting region is a flexible 
domain capable of binding the small protein calmodulin (CaM) in 
L-Argiflifle + 02 
:rulline + N0 
Figure 1.5: Diagram showing the electron flow through the NOS domains during 
production of NO. In the dimer each reductase domain passes electrons to the heme 
domain of the other subunit. 
the presence of calcium. This is quite a common regulating cofactor which in fact 
locks the protein in a conformation that allows the communication between the two 
domains, a condition required for the enzyme to be active. In only one type of 
mammalian NOS, (nNOS) there is an N-terminal region, located upstream from the 
heme domain, which forms a PDZ- binding domain (11), the acronym deriving from 
the first letter of the first three proteins were it was discovered. This region interacts 
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with other proteins or intracellular structures in the organization of signal 
transduction complexes. The NOS dimer is formed by a large interface involving the 
heme domains of each monomer (12), resulting in an overall quasi-globular enzyme. 
Bacterial NOSs are essentially formed exclusively by the heme domain of animal 
NOSs, lacking therefore a N-terminal PDZ domain, the CaM binding intermediate 
region but, most importantly, the reductase domain. They therefore require an 
external source of electrons (13). 
In animals three distinct isoforms of NOSs have been identified, probably descending 
from a common ancestor, considering the high sequence identity of 50 to 60% 
between them (15). These are neuronal NOS (nNOS), inducible NOS (iNOS) and 
endothelial NOS (eNOS), or, respectively, NOS I, IT and Ill. The three isoforms can 
be divided in two other groups; nNOS and eNOS are the two constitutively produced 
enzymes whose activity is regulated by the binding of CaM (16). In the other group, 
iNOS has a very high affinity for CaM such that, when present, it is bound in an 
irreversible way and allows the enzyme to be always active (17). Hence, the activity 
of the inducible form is primarily regulated at the level of its expression, and 
specifically this is started as a response to inflammatory stimuli (18). 
The length of the polypeptide chains of the two main domains are quite similar 
within the mammalian NOS isoforms, with the heme domain of about 500 residues 
and the reductase of about 700 (from residue 221 to 724 and from 743 to 1429 in 
nINOS respectively). The overall mass of a neuronal NOS dimer is consequently of 
about 160 kDa. All the isoforms of NOS have been successfully expressed in a 
variety of expression systems and new bacterial isoforms are continuously being 
discovered and characterized (14, 15). The X-ray crystal structures of the isolated 
10 
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heme domains are available for all isoforms in a number of conditions (e.g. binding 
substrates or other ligands into the catalytical site) and for many bacterial NOSs (13, 
19-22). The structure of the isolate neuronal NOS reductive domain has also been 
determined (23). On the other hand the structure of an entire mammalian holoenzyme 
has not been achieved yet, due to the large size of the protein and the flexibility of 
portions of it. 
11 
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1.2.1 Reductase domain 
The NOS reductase domain is composed of two subdomains, the FMN-domain and 
the FAD/NADPH-domain, positioned in this order along the polypeptidic chain in the 
direction N-terminus to C-terminus. A flexible portion between them allows the 
insertion of the globular FMN domain into the C shaped FAD/NADPH domain 
(figures 1.7 and 1.13). 
Figure 1.7: NOS reductase domain dimer as it appears in X-ray crystal structure. 
Buried into the polypeptide chain are the NADPHs (yellow), FADs (red) and FMNs 
(orange)(23, PDB file: 1TLL). 
12 
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The reductase domain is structurally and functionally related to a family of diflavin 
reductases, including cytochrome P450 reductase. It is thought to derive from the 
fusion of two genes because of structural similarities between the members of this 
family and singularly expressed proteins that resemble either FMN or NADPH/FAD 
domains such as flavodoxins (24) and ferredoxin NADP reductases (25) respectively. 
The substrate (NADPH) and the two cofactors, FAD and FMN (figures 1.8 and 1.9), 
define the domain's role as an electron supplier to the heme domain. They act as 
electron flow carriers, swinging between different reduction states. More specifically, 
the stablility of the partially reduced forms of FAD and FMN (figure 1.10) allow 
single electron donation to the heme starting from the two-electron donor, NADPH in 
the sequence NADPH—FAD--FMN (figure 1.11) (16, 26, 27). 
V I 
0 	 II 	fr 
II 
140-P -0--, 
I 	L—°--- 1 
0=1-OH H 
iN 






Figure 1.8: NADP(H) structure described with details on each group. Highlighted in 
orange is the site of hydride transfer. 
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NI (T N 
N 	N 
H 	 H H 
isoalioxazine ring 
NH 
FM 	 FAD 
Figure 1.9: Diagram of Flavin Mononucleotide (FMN, on dark green background) 
and Flavin Adenine Dinucleotide (FAD, entire structure) showing the common part 
and the isoalloxazine ring which support the different oxidation states of the cofactors. 
Essential tools in the study of electron flow through the reductase domain are external 
electron acceptors, which interact with specificity at different sites. The one-electron 
acceptor ferricyanide, given its small size, is capable of accepting electrons from 
either FAD or FMN. Its reduction rate is then useful to assess the rate at which 
NADPH reduces FAD. 
0 	 0 	 0 
N NH 	))D  fNH fl fNH N 	N 0 	 N 	N 0 e 	 N 	N 
I I I 
R 	 R 	 R 
Oxidised 	 Semiquinone 	Hydroquinone 
Figure 1.10: Different oxidation states assumed by the isoalloxazine rings of FAD 
and FMN. 
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ADP 	ADP ADP 	 AD 	AD 
FA FA FA FA FA 
FMf_ FM k%l FM 	 FM FM 
reductase domain 
heme domain 
or cytochrome C 
Figure 1.11: The catalytic cycle of NOS reductase domain. The different oxidation 
states of the cofactors are described by a colour code, being white oxidized, yellow 
semiquinone and red hydroquinone forms. The sign representing an equilibrium 
means that all the species are present according to a statistical distribution. 
Cytochrome c on the other hand, cannot react with the FAD of NOS, while it can 
irreversibly accept electrons from the FMIN, mimicking the electron donation to the 
NOS heme domain (29, 30). 
The role of NOS reductase domain is to enable the two-electron donor, NADPH to 
reduce the heme, which is a strict one-electron donor. 
The first step of the process is the binding of NADPH. The main interactions holding 
it to the protein consist of a network of hydrogen bonds between the protein itself and 
the negatively charged phosphate substituent. While the binding of the adenine 
moiety is quite strict. The nicotinamide ring of NADPH can be positioned either in a 
15 
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productive conformation, stacking the with FAD isoalloxazine ring, or in an 
unproductive one, far from it. The isoalloxazine ring of FAD must be stacked either 
with the nicotinamide ring or with a conserved phenylalanine residue (F1395 in rat 
nNOS), and the mechanism of displacing each other partitions the enzyme into an 
active or inactive state as a consequence (figure 1.12) (31, 76). This mechanism, as 
well as the secondary structure of the NADPH and FAD binding portion, is shared by 
the large family ferredoxinNADP reductase (FNR) proteins, to which the reductase 
domain belongs. 
a 	 b 
	
K...' 1111 El 393 Hi 
FAVD 	
Hi 032 
Figure 1.12: The reaction of NADPH with FAD: a) the NADPHIFAD domain of rat 
nNOS (32) and b) FNR Y308S mutant (33), showing NADPH binding in 
unproductive and productive conformations respectively. The mutation engineered on 
FNR enhanced the stacking of the nicotinamide on FAD achieving a much ordered 
structure. The corresponding F1395 residue of nNOS must move before stacking can 
occur. 
16 
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FNR generally catalyzes, hydride transfer from FAD to NADP(H), i.e. in the opposite 
direction of NOS reductase domain: a shift in the reduction potential of the FAD 
makes this possible. Being distributed into a productive or unproductive conformation 
at equilibrium, a portion of the enzyme is into the active form and can give rise to the 
first step of the electron flow, the double reduction of the FAD to its hydroquinone 
state. This, although buried in the core of the reductase domain, is in an optimal 
position to interact with FMN (figure 1.13). The two different subdomains are kept 
together by means of salt bridges formed by conserved residues. The FMN 
subdomain has a globular shape and is surrounded by the convex surface formed by 
the FAD/NADPH subdomain such that the isoalloxazine rings are held in an aligned 
position at a distance of 4.8A that is compatible with electron transfer (figure 1.13). 
In its binding site, FAD forms a hydrogen bond with a conserved serine residue 
(figure 1.12), which helps to stabilize its semiquinone form, allowing the passage of 
one electron at time to the FMN. On the other hand, the FMIN semiquinone form is 
extremely stable. Two aromatic residues (Phe809 and Tyr889 in nNOS) stack both 
sides of the isoalloxazine ring and a carbonyl group of the backbone (belonging to 
Gly8 10 in nNOS) forms a hydrogen bond with the N5 nitrogen of the ring system 
(figure 1.14). 
These interactions help to prevent the complete oxidation of FMN. Consequently the 
cofactor uses only the semiquinone and hydroquinone forms as it shuttle one electron 
at a time to the heme domain. 
All NOS isoforms are active exclusively when as dimers. The dimers are stabilized by 
interactions between the heme domains of the two monomers and allow the passage 
17 
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Figure 1.13: The Flavins of nNOS reductase domain are only 4.8 A apart. FMN 
domain (in green) and NADPH!FAD domain (in blue), in this X-ray crystal structure 
(23, PDB file 1TLL). 
of electrons from the reductase domain of one monomer and the heme domain of the 
other monomer that constitute the dimer (34). 
Structural investigations have taking into consideration the length of the protein 
segment that connects the reductase and the heme domains as well as the quaternary 
structure arrangements between the two monomers (23) have shown that the distance 
from the FMN cofactor to the accepting heme could be 70 A. Consequently the FMN 
subunit has to undergo a large structural rearrangements in order to donate an electron 
to the heme, for which the distance limit is about 15 A. 
18 
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FIV G1y810 
Figure 1.14: FMN in its binding site, being stacked by Phe809 and Tyr889, and 
forming a hydrogen bond with carbonyl group of G1y810. This tight net of 
interactions stabilizes the reduced forms of FMN. 
As already said, the region connecting the two domains has the role of binding CaM 
which is of key importance in activating the enzyme for NO production. The CaM 
binding region was first identified by structural homology with other CaM binging 
proteins (35, 36). 
Binding was shown to occur by the protection of the cleavage site from trypsinolysis 
in the presence of CaM (37). CaM is a small protein (less then 17 KDa) formed by 4 
helix-loop-helix Ca2  binding regions arranged in a double globular structure (figure 
1.15). In the presence of a Ca 24  atom, two helixes are held in perpendicular to one 
another resulting in the exposure of hydrophobic residues, which are capable of 
interacting with recognition sites on NOS. The binding of CaM to NOS has different 
features and effects depending on the isotype of NOS. The main difference being 
between iNOS and constitutive NOSs (cNOSs). The latter have an affinity for the 
19 
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Figure 1.15: Structure of Calmodulin binding 4 atoms of Ca 2 (red spheres). On the 
2 right the enlargement shows that in the presence of Ca the two helixes of each motif 
assume a perpendicular position. 
CaM-Ca' complex in the range of nM, while that of iNOS is ten fold higher (KD= 
0.1 nM). Furthermore CaM binding to iNOS is virtually Ca 
2+ independent and 
irreversible (38, 39). 
The different affinities of constitutive NOSs and inducible NOS for CaM rely not 
only on a different CaM-binding region sequence. There are at least two elements 
that differentiate the structure of the various isoforms reductase domains: these are 
an autoregulatory region which sequence is positioned within the FMN-binding 
subdomain of cNOSs and a C-terminal extension of various lengths (figure 1.4). 
Both elements exert their regulatory role with a mechanism that involve the 
interaction with CaM and its binding to NOS. Due to the flexibility of at least a 
portion of both elements none of the reductase domain structure published so far tell 
us about the exact position they have in the different functional conformations of 
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NOS. The determination of their involvement during the regulation of the enzyme 
activity is consequently not entirely revealed. 
The autoregulatory region is an insert of 40-50 amino acids that lowers the affinity of 
constitutive NOSs for CaM with the result of making the enzyme sensitive to 
intracellular changes in Ca 
2+  concentration (16, 28). The insert is in fact in a 
competition with CaM to bind the region between the two flavin domains. In 
addition, a role for the autoregulatory insert as a suppressor of electron flow to the 
heme domain apart from CaM involvement has been inferred (16): a truncated form 
of NOS lacking the insert, showed in fact a suboptimal production of NO even in 
CaM free condition, differently from the wt which has none. 
The C-terminal extension is present in all the three isoforms of NOS but has a 
different length, being 21, 33 and 42 residues long in the inducible, neuronal and 
endothelial forms respectively. The deletion of the extension produces an enzyme 
with higher reductase efficiency in the absence of CaM; the mutant activity has no 
difference with that of the wt when CaM is present (77, 78). The role of the tail is 
consequently that of an interfiavins electron-flow repressor in the CaM-free NOS. 
Further investigations analyzing a NOS reductase domain mutant lacking both the 
insert and C-terminal extension have been made (79); on the basis of this work a 
model relying on the concerted interaction of the two elements with CaM has been 
proposed. According to the model two different conformations are assumed by the 
reductase domain: a locked one where electron flow is allowed within the reductase 
domain, and an open one which lets electron flow to the heme domain. The switch 
between the different conformations is determined by the oxidation state of 
NADP(H): when oxidised (NADP) is then released and no longer interacting with 
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the C-terminal extension, which in turn is no longer capable to contact the 
autoregulatory insert. The loss of this contact determines the conformational change 
that arranges the reductase domain in order to donate electrons to the heme domain 
(open). 
Activation of electron transfer by CaM binding is independent of the heme domain, 
being performed by the purified reductase domain by its own as well. CaM binding 
doesn't affect the reduction potentials of FAD and FMN (42), indicating that the 
triggering effect is based on a deep structural rearrangement that shortens the distance 
from FMN to heme, probably by inducing a degree of conformational mobility. 
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1.3 Herne domain 
The heme domain of NOS is the N-terminal portion of the protein, (although the 
neuronal isotype has a preceding 300 residue PDZ-binding domain, which function is 
in holding together multi-protein complexes) and has a length of about 400 amino 
acids, which binds a b type heme via a conserved cysteine residue through the central 
iron atom (figure 1.16). The heme domains of the different NOS isotype have a strong 
structural homology, ranging from 50 to 60 % for each couple comparison, and 
consequently they share the same overall fold and topology (19). 
JK 	r 
40 
Figure 1.16: A NOS heme domain dimer showing the heme (red) and H413 (green 
with oxygens and nitrogens in red and blue respectively). The H413s lie within the 
dimer interface, which is approximately vertical in the above diagram (PDB file: 
10M4). 
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Considering the heme domain as being composed of subdomains is not entirely 
correct, as the different portions contact each other through surfaces wide enough not 
to be considered hinges. Nevertheless it is quite useful to describe the domain as 
composed by three discrete portions (figure 1.17). The biggest one is that providing 
the residues that interact with the substrate: it has the shape of a crescent with a cleft 
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Figure 1.17: Structures of eNOS heme domain monomers showing different details 
through colour code. On the left panel the three subdomains are shown as green, 
yellow and blue: the substrate-binding, H 4B binding and two-helix bundle 
respectively. On the right panel the colours of the ribbon diagram fade one into the 
other gradually according to the primary structure, starting with blue at the N-
terminal and ending with red on the C-terminal. In both structures H 4B and arginine 
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Figure 1.18: Alignment of the sequences of different NOS heme domains, coupled 
with the secondary structures formed. These are in accordance with the colour code of 
figure 1.17 left panels: arrows stand for n-strands and rectangles for a-helices (43). 
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Diagonally below the heme there is the second and smaller subdomain, mainly 
composed of helices, which provdes the residues contacting I{ 4B. The outer surface of 
this subdomain composes most of the dimer interface, providing a link between 
structural rearrangement upon I-1413 binding and dimerization. Finally below the heme 
plane and on the other side from the H413-binding portion, there is a conserved two-
helix bundle. This has limited interactions with the other two portions and may act as 
a structural reinforcement exploiting the strong hydrophobic interactions between the 
two helices. 
In detail, the residues that interact with the proximal side belong to a mostly N-
terminal portion mainly composed of helices (H5, 1-16 figure 1.19) and a loop that 
provides the thiolate ligand to the heme iron (Cys415 in rat nNOS). 
415 
Figure 1.19: The oc—P motif formed by H5 and S3 positions the iron coordinating 
residue, Cys415 in nNOS. 
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The substrate-binding pocket is formed by residues of the large central n-sheet, 
particularly belonging to the segment Si 1-S 16 (Va1567, Pro565, Tyr588 and 11e593 
in rat nNOS). The heme is surrounded all around its plane by a number of 
hydrophobic residues (Leu424, Leu559, Trp587, Met589, Va1649, Phe704 and Tyr 
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Figure 1.20 
Furthermore two aromatic residues stack the heme from above and beneath (Phe584 
and Trp409 respectively in rat nNOS) keeping their rings on planes that are parallel to 
the heme plane (figure 1.21). 
I 	 Trp409 
Figure 1.21 
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1.3.1 Pterin binding site 
The requirement of H 4B (figure 1.22) is a peculiarity of NOSs. Both the N and 
O H 	OH 	 H 
	
:~H~OH 	 OH 
N )
~' N 't'l 
H 
TetrahydroblOptetlfl (H4B) 	7,84lhydrobioptefifl (H2B) 
Figure 1.22: Structures of H413 and H2B. 
C-terminal portions of the heme domain can be found in different conformations 
depending on the domain being a monomer or a dimer. They are mobile and flexible 
in the first case, but when I-LB is present and the heme domains dimerize the portions 





Figure 1.23: H4B buried in the dimer interface, is stacked by a tryptophan (orange) 
and a phenylalanine from the facing monomer (yellow). The heme propionate H-
bonds with the 3N of the pterin ring (figure H). In the insert is shown H2B replacing 
H413: the planar geometry assumed by its C6 is not as stable as the tetrahedral one 
present in H4B. 
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1- 4B assumes a buried position deep into the dimer interface due to hydrophobic 
interactions (figure 1.16 and 1.22). The ptenne is very unstable in solution, 
undergoing facile double electron oxidation. Its role in NOS catalysis is as a one 
electron donor/acceptor, thus the interactions in the binding site need to stabilize the 
reduced and the partially oxidised form. The stabilization is obtained through a series 
of interactions of a different nature (figure 1.23). The first type of interaction is the 
stacking of a conserved tryptophan (Trp678 in nNOS) which is thought to stabilize 
the I14B radical by mean of it cation interaction. When mutation of this residue was 
performed, even though the protein retained its conformation, formation of the 11 413 
radical was slowed down and the overall reaction disrupted (45, 46). An additional 
stacking of the pterin rings is with a phenylalanine of the other subunit, illustrating 
the importance of dimerization for binding of the cofactor. In addition there is a series 
of H-bonds between the heteroatoms of the pterin rings and the surrounding 
environment, the most important of which is the one between the N3 and heme 
propionate. This is thought to be the preferential path for electron transfer from l -14B 
to the heme-bound oxygen (80). When completely oxidised, as H 2B (figure H) the 
pterin has a different spatial geometry. The C6 on the second ring assumes a trigonal 
planar geometry that, different from the tetrahedral of the reduced form, clashes with 
the environment. The inconvenient geometrical interaction probably exerts a 
restriction that prevents 1-1 413 from oxidising (figure 1.23) (80). 
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1.3.2 The active site 
The substrate channel in NOS has a funnel shape, wide at the entrance and narrow 
going toward the heme (22). The interactions formed by the substrate into the 
channel position it over the heme plane: the nitrogens of the guanidinium group are 
not equally distant from the heme iron, being the proximal the one that undergoes the 








Figure 1.24: The substrate, arginine positioned over the heme plane (PDB 
file: 10M4). 
Residues interacting with the guanidinium group are extremely conserved among the 
isotypes of NOS, the key role in positioning the substrate belonging to a glutamate 
residue (G1u592 in nNOS). Both oxygens of its carboxy terminal form H bonds with 
two nitrogens of the guanidinium group, that close to the a-carbon and the distal one 
(figure 1.25). The latter forms also an H bond with the backbone corresponding to a 
CTI 
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Figure 1.25: Residues limiting the pocket for the guanidinium group of arginine in 
nNOS (PDB file: 10M4). 
conserved tryptophan (Trp587 in nNOS). The space around the distal guanidinium 
nitrogen is evidently tight, and not even a methyl group on this nitrogen is tolerated. 
The allocation of the proximal guanidinium nitrogen is slightly wider: inhibitors with 
up to three carbons on this side are accepted into the cavity, limited by conserved 
proline, valine and phenylalanine (Pro565, Va1567 and Phe584 in rat nNOS) (figure 
1.25). The u-carbon moiety of the substrate lies in a lateral pocket, in respect to the 
main channel, designed to accommodate L-amino acids only. A range of inhibitors 
simply bulkier or without the amino acid substituents extend out of the lateral pocket 
along the main channel and bypass this part. The interactions happening at this level 
determine the specificity of inhibitors in respect to the isotypes. The H bonds formed 
between the protein and the terminal u-carbon of the substrate involve the hydroxyl 
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Figure 1.26: Residues forming the pocket that binds the carboxylate of arginine. 
of Tyr588, the carboxylate of Asp597, Lys478 and a water molecule held by Arg603 
with the carboxylate of the substrate; the a amino-group on the other hand interacts 
with the previously mentioned Glu592 and the heme propionate (figure 1.26). 
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1.4 Cytochrome P450 
Cytochromes P450 are a large family of enzymes named after the peculiar absorption 
peak formed upon CO binding (47, 48). They usually perform mono-oxygenation 
reactions, namely the insertion of an atom of oxygen, in order to hydroxylate a variety 
of substrates, exploiting the activation of molecular oxygen (figure 1.27). 
RH + 02 + 2W + 2e 	ROH + H 20 
Figure 1.27: The generic mono-oxygenation reaction catalyzed by P450s. 
This reaction if uncatalyzed would require extremely high temperatures to happen. 
Hydroxylation of non-activated hydrocarbons often increases their hydrophilicity, 
facilitating their excretion from the organism. Also, hydroxylations performed by 
P450s are key steps in various synthetic and metabolic pathways (49, 56). A 
digression into P450s forms a usefull introduction to the NOS reaction due to the 
similarities of the reactions performed and of the active site cofactors, both of which 
are a b-type heme with a thiolate iron ligand. However, it should be noted that the 
structures of NOS and P450s are entirely unrelated. 
The involvement of P450 in progesterone metabolism, demonstrated in 1963 (49), 
triggered a chain reaction of growing interest that led to the present situation, where 
the structures of many members of the family have been solved in a variety of 
conditions (50-52) and the catalytic cycle is known in detail for a large part of it (53, 
54). Focusing on the structure shows how P450s and NOSs have achieved the 
performance of a similar reaction through convergent evolution. P450s are in fact 
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made of mainly helical structures, unlike NOSs, and share the same global folding 
and tertiary structure even when the sequence homology is low (e.g. 15 %) (figure 
1.28). The heme is generally sandwiched by four helices that provide the catalitically 
important conserved residues, such as the cysteine that coordinates to the iron (figures 
1.29 and 1.30). Having a cysteine as fifth ligand, is a feature shared by P450s and 
NOSs. The strong electron donating nature of the thiolate is thought to activate 







Figure 1.28: Three different examples of P450 enzymes sharing the overall helices 
predominance, particularly for what concern the engaging of the heme (in orange). 
A small pocket above the heme is always present in P450s and allows a molecule of 
water to coordinate to the iron during the resting state of the enzyme (figure 1.29); 
this water is often displaced by the substrate binding, causing a change in the spin 
state of the iron. 
It is difficult to generalize about the substrate binding site given the huge variety of 
substrates processed by the family members. The examples in figure 1.30 show how 





Chapter 1: Introduction 
(P450nor) (81) to a large one like epithilone (P450epok) (82). Even when the 
substrates are similar, a high homology is not obvious; this the case of P450cin and 
P450cam, hydroxylating cmeole and camphor respectively having an identity of only 
26% (83, 84). 
I 	H2O 4ØV Thr 
Figure 1.29: The P450s heme is coordinated by Cys on the proximal side, and H20 
on the distal side. A catalytically important Thr residue is within H-bonding distance 
of the bound H20. 
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Figure 1.30: Examples of molecules that serve as P450 substrates 
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1.4.1 Supporting redox partner 
P450s can be divided in two main groups depending on the way they have their 
electrons supplied (except there are several unique combinations not belonging to any 
of the class) (figure 1.31). Class I P450s have a redox partner made of two 
components delivering the electron equivalents generated by NADH dehydrogenation. 
The first component, Ferredoxin Reductase, binds NADH and uses FAD as a cofactor 
to accept the hydride. Electrons are passed to a second protein, the iron-sulphur 
cluster containing Ferredoxin. The electrons are then transferred to the heme of P450. 
This arrangement is common in bacterial and mitochondrial P450 systems; in bacteria 
the complex are usually soluble (P450cam (85)), while in mitochondria are 
commonly bound to the membrane (P450scc (86)). Class II P450s have Cytochrome 
P450 reductase as a redox partner. This protein closely resembles the NOS reductase 
domain. It binds FAD and FMN and uses them to deliver NADPH-derived electrons 
to the heme. This system is common to microsomal proteins, being the complex 
bound to the cytoplasmic side the endoplasmic reticulum (P450 2C5 (87)). When a 
homologue of Cytochrome P450 reductase and a P450 are fused together in a unique 
enzyme they are called a Class ifi P450, a minor group. 
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Figure 1.31: Representation of the different classes of cytochrome P450. P450 
domains are in red and redox partner components in yellow (FAD domain), green 
(FMN domain) and blue (Iron-sulphur cluster). A: class I system comprised of FAD, 
iron sulphur and P450 subunits. B: class II system comprised of FADIFM}4 reductase 
and P450 subunits. C: class Ill system formed by fused FAD/FMN reductase and 
P450 domains. Panels D and E: other unique combinations of redox cofactors such as 
P450 RIif and P450 cm. 
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1.4.2 The catalytic cycle of P450 
In order to perform the reaction, the first aim for the P450 is the activation of 
molecular oxygen that otherwise, in its triplet state, would not react with the singlet-
state majority of substrates. Metals are commonly used for this purpose by enzymes, 
being in this case the heme-iron that binds the oxygen and stabilizes the highly 
reactive transients as the reaction proceeds. In addition to the oxygen binding, two 
sequential one-electron reductions are necessary for P450 to perform its reaction: 
these steps produce a series of intermediates that lead to the formation of the reactive 
species. A diagram showing all the steps of the reaction is shown in figure 1.32. 
Substrate binding. The first step of the reaction is the binding of the substrate that 
nearly in all the cases displaces the loosely bound sixth iron ligand, a molecule of 
water (52, 88, 89). In P450s the binding of substrate has the effect of causing a heme 
spin state shift from low to high, but most importantly and differently from NOS, the 
displacement of the water has a destabilizing effect on the ferric form of the enzyme 
causing a heme reduction potential shift of about ±lOOmV. The enzyme swings then 
from a substrate-free state where uncoupled hydride consumption is prevented, to a 
substrate bound one where the heme reduction is viable. 
First electron transfer. The first electron, as well as the second, is provided by the 
redox partner-bound NAD(P)H. Molecular oxygen, which has high affinity only for 
the ferrous heme, then binds. In some P450 enzymes the heme reduction may induce 
structural rearrangements that bring the substrate closer to the heme, as an additional 
control element of the reaction coupling (90). 
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Figure 1.32: General scheme of the P450 reaction: 1: substrate binding, 2: first 
electron transfer, 3: Oxygen binding, 4: second-electron transfer, 5: formation of 
oxy-ferryl species, 6/7: rebound mechanism for oxygen insertion and 8: product 
dissociation. The 1, 2 and 4 electron uncoupling pathways to superoxide, peroxide 
and water are shown as dotted lines. 
Oxygen binding. Molecular oxygen binds rapidly to the ferrous heme. The complex 
could be described either as oxy-ferrous (Fe 11-02) or as the isoelectronic superoxy-
ferric form (Fe"-02). 
Second electron transfer. As already mentioned a second electron is accepted and 
gives rise to the formation of a peroxy-ferric species (Fe"-00 2 ). In some atypical 
P450 reactions the latter is the reactive compound towards the substrate. This is the 
case in P450 aromatase, which performs the removal of a methyl group as a step in 
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the synthesis of some steroids. The enzyme performs a three-step reaction., the third 
of which cannot be explained by the action of the usual P450 oxy-ferryl compound 
(92). 
Protonation. The reaction proceeds via a double protonation, the first of which 
produces a hydroperoxy-ferric intermediate (Fe"-OOH). The hydroperoxyferric 
compound has also been suggested to be in some cases the reactive species, being 
reactive enough to perform the oxygenation especially when the second protonation is 
slow (91). However it is generally accepted that the hydroperoxyfemc species is 
protonated and subsequently decays by loss of a water molecule to form a highly 
reactive carbocationic oxy-ferryl species (FeIf),  known as Compound I. 
and 7) Oxygen insertion. The oxy-ferryl compound is thought to abstract a 
hydrogen atom from the substrate, creating, on one side a substrate radical species, 
and on the other a hydroxyferric heme. The hydroxylation step is then a rapid 
radical-recombination, resulting in ferric heme. This global mechanism is called 
Rebound and is graphically described in figure 1.33. 
8) Product dissociation. The hydroxylated product is released from the ferric heme 
which binds a new molecule of water as sixth ligand. 
Of all the intermediates shown in the catalytic cycle (figure 1.32), the oxyferrous 
compound arising from the binding of molecular oxygen to ferrous enzyme is the last 
one that can be observed with classic spectroscopic techniques (UV-Vis 
spectroscopy) in physiological conditions. The identity of the subsequent 
intermediates is only inferred. These were initially derived from comparison with 
structurally and functionally similar enzymes, in particular Chloroperoxidase (CPO) 
and Horseradish Peroxidase (HRP). In the last two decades there has been made an 
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Figure 1.33: Graphical description of the rebound mechanism of oxygen insertion. 
The oxy-ferryl binds substrate and abstracting a proton fenerate a substrate radical; 
this radical rebinds the heme-hydroxyl group hrough the oxygen before being 
released in its hydroxilated form. 
extensive spectroscopical characterization of the intermediates produced by the 
second electron transfer: peroxyfernc, hydroperoxyferric and oxyferryl compounds. 
Electron Paramagnetic Resonance (EPR), Electron-nuclear Double Resonance 
(ENDOR) and Raman Spectroscopy have been giving information about the identity 
of the compounds forming during the course of the reaction, especially when these 
techniques are coupled with stabilizing conditions such as low temperature and 
mutagenesis (93-95). 
In a recent work (96) structures of three transients formed during the oxygen 
activation process in P450cam have been determined by freeze-trapping the different 
complexes. Schlichting et al. exploited the ordered and contemporaneous manner 
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with which the enzyme in the crystals initiates the subsequent steps of the reaction 
and obtained a homogeneous sample of intermediates. They used short-wavelength 
X-ray irradiation to solve the structure of the ferrous and oxygen bound enzyme so as 
to avoid further reduction during data collection. On the other hand they used long-
wavelength X-ray irradiation on the oxyferrous low-temperature stabilized enzyme 
crystal, with the intent of triggering the second electron delivery to detect the newly 
formed intermediate, the putative oxyferryl compound. The electron density map they 
have obtained upon this treatment suggests the presence of a mixture of species: the 
comparison with the dioxygen-bound enzyme indicates that the predominant species 
in this case has a single oxygen atom bound to the heme iron. 
1.43 The catalytic role of a conserved Threonine 
TheP450 family is very large and there are many differences between the members, 
compared with the few conserved characterizing common features. One of these is 
the extensive presence of a conserved threonine residue (Thr 268 in P450 BM3 and 
Thr 252 in P450cam) (figure 1.29). This residue belongs to the helix above the heme 
that provides the pocket where a water molecule is acting as a sixth ligand in the 
resting state enzyme; the water is in fact within H-bonding distance of the threonine. 
Many roles have been proposed for this residue such as oxygen activator, proton 
provider, electron donor, element of recognition for the substrate and heme-water 
ligand (97-101). The results of part of the work that aimed to clarify the role of this 
residues are sometimes controversial: e.g. the threonine was mutated to alanine and 
showed evidence for the involvement of this residue in the binding of oxygen during 
its activation course (97). On the other hand a recently published structure of the 
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oxygen-bound enzyme indicates that no hydrogen bond is formed between the 
threonine and the oxygen (102). Hence further investigation is needed to identify the 
role of this key threonine, taking in consideration the possibility that it may have 
different roles in the different members of the family. 
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1.5 Catalytic Reaction of NOS 
The conversion of L-Arginine to NO takes place in two steps: first the formation of of 
L-NOHA and then the conversion of this to L-Citrulline and NO (figure 1.34). Both 
steps begin with the stepwise activation of molecular oxygen., through the formation 
of complexes with the heme. The reactive species are formed in order to hydroxylate 
the substrate in the first cycle and perform an oxidative scission on it in the second 
one. The present chapter will give a detailed description of the intermediates formed 
and of the efforts made to reveal their identities. 
Figure 1.34 shows the two cycles of the reaction in terms of the heme states formed 
(62). In the text, as well as in the scheme through different background colours, the 
reaction will be divided into three phases for convenience of explanation. The phases 
are: 1) first electron transfer and oxy-ferrous species formation (yellow) 2) electron 
transfer from 114B (orange) 3) formation of reactive heme-oxy species, 
monoxygenation and NO release (red). While in the scheme the two cycles are 
assumed to be identical for simplicity, within the text the differences will be 
discussed. 
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Figure 1.34: Overall scheme of the reaction. The three phases described in the text 
are here divided by colour code, being yellow, orange and red the first, second and 
third respectively. The electron transfers are shown in green, reductions being light 
green and oxidation darker green. 
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1.5.1 First electron transfer 
02 
Fe" 	Fe" . [ Fe'L0 2 Fe"-0 2
] 
In contrast to the P450 reaction, in NOS substrate binding does not act as an enhancer 
of the first electron transfer by modifying the heme reduction potential; neither does 
I-14B. On the other hand the binding of substrates arginine or NOl-IA determine a shift 
from mixed low/high to entirely high in the spin state equilibrium of the heme: this is 
due to the displacing of a weakly bound water molecule acting as a distal sixth axial 
ligand to the iron heme. This is reflected in a Soret peak shift from 400 run, that of 
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Figure 1.35: NOS spin-state shift from mixed low/high to high upon substrate 
binding 
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The electron provided by the reductase-bound FMN reduces then the heme ferric 
iron (Fen ) to its ferrous form (Fe ll) (58, 59). This transformation results in a shift of 
the UV-Vis spectrum with the Soret peak going from 395 nm to 414 nm (figure 1.36); 
also a smaller but broad peak in the region of 560 nm forms in place of the two slight 
bumps at 530 and 650 nm that characterize the ferric heme spin state. The ferrous 
form has a dramatically increased affinity for oxygen and at this point oxygen binds 
to the iron on the distal side of the heme plane to form the oxy-ferrous compound. 
There is a red shift in the Soret maximum to 425 nm and some flattening in the 
500/600 nm region (Figure 1.36). On the other hand when the substrate-free enzyme 
in its ferrous form is mixed with oxygen there is no accumulation of the oxyferrous 
compound. This indicates that in absence of substrate the rate at which the oxyferrous 
compound decays is faster than its rate of formation, suggesting a stabilizing role for 
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(nm) 
Figure 1.36: UV-Vis spectra of nNOS 0,, ferric (black), ferrous (red) and oxyferrous 
(yellow) forms. 
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In NOS the peak of the oxyferrous compound is slightly red-shifted if compared with 
those formed by the majority of P450s: those are ranging around 418420 rim (e.g. 
oxyferrous compound of P450cam and P450LM) (103, 104). Nevertheless there are 
some cases where the similarities are unambiguous (e.g. Oxy-Ferrous compound of 
substrate bound Cytochrome P450 SCC) (60). This species is named either Oxy-
Ferrous (Fe"-02) or Ferric-Superoxy (Fe' 11-02) and is a resonance form of the two 
isoelectronic compounds. Its formation is first order dependent on oxygen 
concentration. 
In the absence of either substrate or pterin, or both, the enzyme is directed into an 
uncoupled unproductive cycle, that is the usage of part or all the electrons for the 
formation of a compound other than the product; in case of a substrate-free enzyme, 
regardless of the presence of pterin, the autooxidation of the heme oxy-ferrous 
species produces superoxide anion (02) (62). In the presence of H 4B the rate of the 
oxyferrous compound decay varies greatly depending on the presence of substrate; in 
the substrate-free NOS the oxyferrous compound decays more quickly (>160 s - 1 ) than 
it does as part of a productive cycle in the presence of substrates (22 and 4.9 s_ I in the 
presence of arginine and NOHA respectively) (63). Finally when both H4B and 
substrate are present, the oxyferrous complex undergoes further reduction. 
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1.5.2 Second electron transfer 
FRV4ç FW4 
+ 
H4B j1, 1 B• 
I Cycle 	[Fe"-02 Feu°-Oj] _ I Fell'-02 2-  
H4B iit 	
2. 
2nd Cycle [Fe"-0 2 Fe"-0 21_ 
The events involving the oxy-heme compounds in the course of the reaction are no 
longer producing accumulating intermediates from now on. This is reflected in the 
fact that none of the transients are detectable by UV-Vis spectrometry, and hence 
after the identification of the oxy-ferrous compound by means of its UV-Vis 
spectrum, the next species we can identify is the resting ferric heme formed after the 
completion of the reaction, this being either the hydroxylation of arginine or the final 
cleavage that produces NO and citmiline. 
Nevertheless, it is accepted that the second electron delivery leads to the formation of 
a Ferric-Peroxy species, this being the first of a series of compounds in a "black box" 
of which we can observe only the final result, either in the first or second cycle. A 
glimpse into the "black box" is provided by very low temperature studies. Davydov 
and co-workers (64) induced the second electron delivery to a competent NOS oxy-
ferrous heme through y-irradiation at 77 K. Both EPR, but particularly ENDOR 
characterization confirmed the identity of the newly formed transient to be that of a 
Ferric-Peroxy heme species, hydrogen bonding to a water molecule just above the 
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heme plane. The ENDOR spectrum resembles that formed upon identical treatment at 
77 K of a P450cam mutant where the mutation induced loss of the water molecule 
binding in the distal pocket (65). In the cryoreduction of the wild-type oxy-ferrous 
compound a protonated form of the Ferric-Peroxy compound was generated, while 
the lack of a protonating facility in the mutant produced the same species as observed 
in NOS. 
The identification of the second electron source during oxygen activation in NOS 
involved a huge amount of work. The requirement of NOS for H413 in order to 
produce NO suggested a possible unusual role of the pterin as donor of the second 
electron: the first evidence for this hypothesis was given by the detection of a H 4B 
radical (H413) after Rapid Freeze Quenching when arginine-bound Ferrous NOS was 
mixed with oxygen; the formation of the radical occurred at the same rate as the 
decay of the oxy-ferrous species (69). Radical formation was detected at 0.75 per 
heme, coupled tightly with oxy-ferrous decay in a monophasic reaction. To 
countercheck the role of H 413, a number of different reaction-conditions have also 
been investigated. In the presence of amino-144I3 (an analogue which promotes 
enzyme dimerization but has no capability to donate an electron) the enzyme forms 
the oxy-ferrous compound, which autooxidises slowly (63). When H 413 is replaced by 
5-methyl-RiB the enzyme retains its capability to perform an arginine hydroxylation 
in a single turnover cycle, but the formation of the pterin radical happens 3-fold faster 
than with I-LB (70). This is coupled with a 3-fold faster rate of oxy-ferrous decay. 
The role of H413 in the second cycle of the reaction has been clarified only recently, 
due to the difficulties to detect its radical form: only a small fraction of radical per 
heme (about 3% of the heme content) was detected during a single-turnover reaction 
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of NOHA-binding NOS (69). The difficulties in detecting the H 413 radical may be due 
to its fast disappearance, being quickly reduced back during the last part of the 
reaction. 
When reacting with the oxyferrous complex in the presence of arginine, H 4B donates 
an electron forming a H4B radical that is ultimately reduced back to H 413 during 
catalysis, possibly by a NADPH derived electron. In the presence of NOHA H 4B 
oxidizes and then is promptly reduced back by the ferrous NO-complex formed at the 
end of the monoxygenation step. This process is essential to explain how the 
formation of NO and ferric enzyme ultimately occurs. The ferrous NO-complex is too 
stable to release NO spontaneously. Therefore there is a double role for H 413 as an 
electron donor and as an acceptor during the second cycle reaction (67). 
1.53 Formation of the ultimate reactive species 
H4 	 H 
F&"-022- -- Fe°'-O-OH —i-- FeItL0OH 2- Fe"O 
Although theoretically the Ferric-Peroxy compound could be reactive towards both 
arginine and NOHA, is generally accepted that this compound undergoes a double 
protonation and through the loss of a water molecule produces what is considered the 
ultimate reactive species. This is also the putative reactive species of most P450 
reactions, the Oxy-Ferryl also called Compound I (Fe "). Unlike in other molecular 
oxygen activating enzymes (67, 74), the Ferric-Hydroperoxy compound resulting 
from the first protonation has never been observed, not even after low temperature 
reduction and annealing of the Ferric-Peroxy compound. This could strengthen the 
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hypothesis that the Ferric-Peroxy complex is the active species. Nevertheless after 
cryoreducion the two-proton delivery is inferred from the detection of a species that 
can be formed exclusively through two consecutive protonations and the production 
of a water molecule: a heme-substrate adduct where the substrate is already 
hydroxylated and coordinated to the ferric iron through the oxygen of the hydroxyl 
(figure 1.37). The only way for this to happen is that a double protonation weakens 
the oxygen-oxygen bond in the Ferric-Peroxy complex until it breaks producing 
water, the overall process leading to the formation of Compound I: the latter can then 
attack the arginine nitrogen to form the adduct observed (64, 65). If the attack on 
nitrogen were performed before the breakage of the 0-0 bond by means of the 
Oxy-Ferryl Pathway 
K-? -- 	"N 













Figure 1.37: Oxy-ferryl pathways for the attack on the substrate. There are evidences 
for the formation of the adduct on the top of panel. 
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distal oxygen, the presence of the heme-NOFIA intermediate would be difficult to 
justify (also at 200 K NOHA, after its production, coordinates with the Ferric heme to 
form an unstable complex) (figure 1.37). The Fe-O distance in the adduct increases 
stepwise until NOHA is released, remaining enzyme-bound in the catalytic site to 
undergo the final part of the reaction. 
AM NOHA 
Fe'O_ _)  Fe" 
In the second cycle the attack is performed on the hydroxylated nitrogen of NOHA 
and NO is synthesized through the utilization of this nitrogen (75). Once produced 
NO is bound to the Ferrous heme which is then oxidised before it can be released. 
NOHACjtjiine 	 H4SH4B 	 NO 
FeO_ 	Fell-NO_ Fell'-NO -0  F&" 
The affinity of NO for the Ferrous heme is much higher and its release would not be 
possible, forming a dead-end complex instead. For this reason NOS has two different 
electron-sources. Optimization of electron delivery from the Reductase Domain, in 
order to provide the second electron as well, would in fact increase the fraction of 
enzyme forming the unproductive Ferrous-NO heme due to the possibility of the 
Ferric-NO complex being reduced. 
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1.6 Aims of the project 
The aim of this research is to further understand the final part of the reaction 
performed by NOS that leads to NO production. As thoroughly discussed in the 
Introduction the reactive species formed in the heme domain catalytic site have been 
identified only up to the formation of the Oxy-Ferrous compound. The events taking 
place thereafter are not obvious due to the lack of accumulation of the intermediates 
forming. A higher resolution picture of the species succession during NOS reaction 
could lead to a wider knowledge of the elements that determine oxygen reactivity. 
This type of information is essential in the attempt to develop specific NOS-
inhibitors. Drug development based on the reaction mechanism comprehension is 
important in relation to the large number of diseases in which anomalous NO 
production is involved. 
Different approaches have been used to gather information about the identity of the 
intermediates formed upon oxygen activation into the NOS catalytic site. Analysis of 
the catalytic reaction has been performed at very low temperature in the attempt to 
trap and characterize the intermediate (64, 69). Also H 413-analogues have been used 
to characterize reactions triggered by the second electron delivery (63, 70). 
Our approach in the understanding of the NOS reaction involves a preliminary 
analysis of the enzyme catalytic site: amino acid residues in the distal portion of 
NOS heme domain are involved in the stabilisation and activation of the oxygen-
heme complexes formed during NO production. The interactions they form with the 
transforming species have the task to promote oxygen binding, prevent uncoupled 
reactions and assist punctual 0-0 bond breakage. Inspection of the distal side of the 
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catalytic domain reveals a striking hydrophobic character of the residues which may 
interact during the reaction: surprisingly there are no residues capable of hydrogen-
bonding to heme-bound oxygen. The reaction performed by NOS is similar to that 
performed by cytochrome P450, where hydrophilic residues play a key role during 
the activation of oxygen. An amino acid residue with the ability of forming 
hydrogen-bonds at a suitable distance from the space where substrate and oxygen-
heme complexes interact may introduce species stabilization during the course of 
oxygen activation. With this in mind a series of mutant of nNOS".,y were generated, 
expressed and purified. They were then tested for their catalytic behaviour by means 
of stopped flow experiments. The identification of a mutant showing the capability to 
stabilize at least one new intermediate of the reaction is the main aim of this project. 
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2 MATERIALS AND METHODS 
2.1 Mutagenesis 
All neuronal NOS heme domain constructs were created by Dr. Caroline S. Miles, 
Institute of Cellular and Molecular Biology, University of Edinburgh. The NOS G5865 
heme domain mutant characterised was generated by site-directed mutagenesis using the 
Kunkel method (105). The E.coli strain BL2 I was used for the expression of both wild 
type and G5 86S mutant constructs using plasmid pCRNNR (106). During the creation of 
both wild type and G586S constructs, an N-terminal histidine tag was added to the 
plasmid in order to purify the enzymes exploiting their affinity for nickel. 
2.1.1 Cell transformation 
30 p1 of competent cells BL2 1 E.Coli were gently defrosted on ice before 5 to 10 ng of 
plasmidic DNA in a volume of I to 5 ptl were added and mixed. The mixture was 
incubated for 30 minutes on ice and then heat shocked at 42°C for exactly 30 seconds in 
a water bath before being quickly placed on ice again. Pre-warmed SOC medium (see 
table 2.1) (250 p1) was added before transferring the vial at 37°C for 1 hour in a shaker 
at 225 rpm. Eventually, different aliquots (10 to 100 1.11)  of the transformation mix were 
plated onto two LB plates containing 25 mg/ml carbenicillin and 35 mg/ml 
chloramphenicol: a flame sterilised loop was dragged across the surface of the cells-mix 
and used to streak out the agar plate. The plates were incubated overnight at 37 °C in 
order to promote the growth of bacterial colonies. 
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2.2 Expression and Isolation 
Cell cultures for line-maintenance were prepared for both wild type and G586S mutant 
enzyme. Small amounts of cells were picked from the colonies on LB-agar plates with a 
sterile wire loop and dispersed into 30 ml of sterile TB augmented with 25 mg/ml 
carbenicillin and 35 mg/ml chloramphenicol in sterelin tubes. 
Table 2.1: Growth Media and Agar 
Luria Bertani Broth (LB) For I litre: 10 	Bacto Tryptone 
5 gYeast Extract 
5 g NaCl 
Terrific Broth (TB) For 1 litre: 20 g Bacto Tryptone 
10 gYeast Extract 
4 ml Glycerol 
2.6 g K142PO4 
4.3 g K2HPO4 
Prepared using MihiQ ultrapure water (of resistivity 18 I cm') and autoclaved sterilized. 
LB Agar Plates 15 gL' agar dissolved in LB 
Autoclaved agar was allowed to cool to room 
temperature. Prior to setting, agar was augmented 
with 	25 	mg/ml 	carbenicillin 	and 	35 	mg/ml 
chloramphemcol and poured into Petri dishes. 
S.O.C. Medium For I litre: 5 g Bacto Tryptone 
5 gYeast Extract 
0.58 g NaCI 
0.19 gKCI 
1.2 g MgSO4 
2.0 g M902 
3.6 g Glucose 
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The cells were then incubated overnight at 37.5 °C and 150 rpm in an orbital 
shaker/incubator. From these starter-cultures small stocks for future use were prepared 
by adding 77 il DMSO to I ml of cells dispersion (7% DMSO by volume). DMSO 
stocks were then stored at -80 °C until required and kept at low temperature while in use. 
The DMSO stocks were replaced periodically using cells colonies from freshly prepared 
LB agar plates. 
Aliquots of 2 ml from the starter cultures were inoculate in each flask containing larger 
quantity of TB media: typically 40 x 350 ml TB augmented with 25 mg/ml carbenicillin 
and 35 mg/ml chioramphenicol in I litre baffled flasks were used. The flasks were kept 
at 37.5 °C and 150 rpm in an orbital shaker/incubator until the optical density (O.D.) of 
the culture was in the region 0.5 - 0.8 (---6 hours). IPTG (24 mg/ml) and ATP (113 
mg/ml) were then added to induce overexpression. The temperature was lowered to 20°C 
for a period of 20 hours. 
The cell rich media was eventually collected and the cells harvested through 
centrifugation at 15 000 rpm for 15 minutes at 4°C (Sorvali RC-5B centrifuge with a 
SLA 3000 head). The cell pellets were collected and stored at -20 °C until required. 
2.3 Extraction and Purification 
2.3.1 Cell Extraction 
Cells stocks were defrosted and suspended in Resuspension/Lysis buffer (table 2.2) 
allowing approximately 40 ml buffer for 25 g of cell pellet. Lysis of the E. coil cells was 
obtained through air-bubble generation by ultrasonication using a Sanyo Soniprep 150. 
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Typically 8 sonication turns of 20 second each at 15 microns applied to a 40 ml cell 
suspension were required to lyse cells. The beakers containing the cell suspension were 
kept on ice to prevent overheating between one sonication and the other. Eventually the 
lysate was pooled and cell debris separated by centrifugation at 20 000 rpm for 1 hour at 
Table 2.2: Purification Buffers 
ResuspensionlLysis Buffer 50 mM Tris-HCI (pH 7.5) 
0.5 mM EDTA 
10% glycerol 
20 pM H4BIaminoH4B 
1 mM dithiothreitol 
25 mM phenylmethylsulfonyl fluoride (PMSF) 
20 mM imidazole 
0.1mM L-argmme 
0.3 M NaCI 
protease inhibitor (1 tabletl50ml buffer) 
Elution Buffer 50 mM Tris-HCI (pH 7.5) 
0.5 mM EDTA 
10% glycerol 
20 tLM H4B/aminoH4B 
1 mM dithiothreitol 
150 mM imidazole 
0.1mM L-arginine 
0.3 M NaC1 
Gel Filtration Buffer 50 mM Tris-HC1 (pH 7.5) 
20 i.tM l-LB/aminol-14B 
1 mM dithiothreitol 
Prepared using MilliQ ultrapure water (of resistivity 18 Q cm') and pH adjusted using HCI 
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4°C (Sorvall RC-B5 centrifuge with a SS34 head). The supernatants containing the over-
expressed nNOS were collected and kept on ice prior to the chromatographic steps of 
purification. 
2.3.2 Column Chromatography 
All protein purification steps were carried out in a cold-room at 4°C using purification 
buffer A. 
The purification profiles for the wild type and G586S nNOS0,, constructs are the same. 
Nickel Sepharose Affinity Chromatography: Ni 2l  Sepharose prepacked column is formed 
by agarose beads cross-linked together bringing immobilized chelating groups binding 
in turn nickel (Ni 2 ), The high affinity of the six-histidine tag on both nNOS,,, y  for Ni2 
make the binding very selective and allows an extremely high degree of separation from 
all the other proteins in the lysate. We exploited this affinity during the first step of 
nNOS03 , purification: the lysate was loaded onto a HisTrapllP 5 ml Column 
(Amersham) using a FPLC system (Akta Purifier), the flow being very slow (0.5 
ml/min) to maximize the protein binding. The column was then washed with 
Resuspension/Lysis buffer until the UV Absorbance at 400 nm was stable. Elution was 
then performed using Elution Buffer, allowing high concentration imidazole to displace 
the histidine tag in Ni 2 binding then letting the protein flow through the column. The 
red/brown coloured fractions were collected, and a further selection was made to 
increase the purity of the enzyme retaining only the fractions showing high content in 
heme (UV-Vis absorbance at 400 nm). To prevent the inclusion of heme-containing 
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deleted forms of the enzyme SDS-PAGE analysis (paragraph 2.5.1.2) was carried out on 
the fractions collected: only the fractions showing a highly pure presence of the 80 KDa 
monomer were pooled. 
G-25 Size Exclusion Chromatography: Gel filtration was used as last step of purification 
to eliminate the excess imidazole present due to elution from the agarose-Nickel column. 
The G-25 size exclusion chromatography beads contain pores of a precisely regulated 
size allowing only small molecules to enter into the beads. As a result molecules with a 
bigger size than that of the pores (e.g. enzymes) pass through the column faster than 
small molecules (e.g. imidazole) which path is considerably longer. To prepare the 
column freeze dried G-25 sephadex was suspended in Gel Filtration Buffer (table 2.2) 
and packed by gravity. The column was then thoroughly washed with the same buffer 
prior to use. The collected fraction from agarose-Nickel column in a volume not greater 
than 30 % of the G25 column volume was loaded onto the top of the column and eluted 
by addition of more buffer. The red-coloured imidazole free fractions were collected. 
2.3.3 Dialysis 
When substrate-free riNOSoxy was needed, the enzyme solution collected from Gel 
filtration column was dialysised overnight (12 kDa exclusion limit) at 4 °C into 5 litres 
of Gel Filtration Buffer enriched with 0.5 M imidazole: in this way residual L-arginine 
bound to the enzyme was displaced by imidazole. Dialysis against Gel Filtration Buffer 
in order to remove imidazole was then repeated several times until UV-Vis spectrum of 
substrate free enzyme was detected. 
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2.4 Concentration and Storage 
Concentration of the purified protein was obtained via centrifugation using a FALCON 
6-300 centrifuge at 2000 rpm and Amicron Centriprep concentrators with a membrane 
size of 30 kDa. Protein concentration was spectrophotometrically measured and 
concentration was repeated until in the region 100 riM. The enzyme solution was then 
divided into aliquots, flash frozen in liquid nitrogen and stored at -80°C until required. 
2.5 Characterisation 
2.5.1 Purity Determination 
The purity of the protein was measured at several stages by both analysis of UV/vis peak 
ratios and by SDS-PAGE (Sodium Dodecyl Sulfate-Poly Acrylamide Gel 
Electrophoresis). 
2.5.1.1 Peak Ratios 
UV/vis spectra of the enzyme were recorded over the range 200 - 800 nm using a 
Shimadzu IJV-2I0IPC spectrophotometer. The solution was put in quartz cuvette with 
a 1 cm path length in a total volume of I ml (typically 10 j.il of purified protein diluted in 
990 tl get filtration buffer). The purity was measured through the ratio of absorbances 
values at 280 nm (global content of proteins) and at 395-4 10 nm depending from the 
conditions of purification (Soret peak for heme in nNOS). The ratio A280:A400 for purity 
higher than 95% was found to be about 2:1 (figure 2.1). 











Figure 2.1: UV-Vis spectrum showing nNOS0 Soret peak (400 nm) and global protein 
content peak (280 nm). 
2.5.1.2 Gel Electrophoresis 
SDS-PAGE (Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis) was 
performed using NuPAGE® Novex 4-12 % Bis-Tris pre-cast polyacrylamide gels in 
combination with SeeBlue Plus 29 molecular weight markers. 
Assessment of the purity and integrity of the enzyme was carried out through gel 
electrophoresis at different stages of the expression/purification. The protein samples or 
cell pellets were diluted using buffers as described in table 2.3 and boiled for 3 minutes 
to denature the protein and allow SDS binding. SDS bind with a constant ratio to the 
proteins as a function of their mass (1.4 g SDS:lg protein) and shields their charges, the 
different distances at which every protein migrate depending only on its mass. 
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Table 23: SDS PAGE buffers and stains 
Sample Buffer 25 	tl NuPAGE® LDS 4x Sample preparation 
buffer pH 8.4 
25 t1 diluted protein sample (>1 riM) or 
25 jil lysed cell pellet (0.03 gml') 
50 j.il d1420 
Running Buffer NuPAGE® MES SDS 20x Running buffer 
pH 7.0 
Coomassie Stain 50 ml dH20 
40 ml Methanol 
10 ml Acetic Acid 




40 ml Methanol 
10 ml Acetic Acid 
Prepared using MiIIiQ ultrapure water (of resistivity 18 Q cm -1 ). 
The central reservoir was filled with running buffer ensuring that the buffer-level was 
beyond the sample loading wells. Aliquots of each sample ranging from 5 to 15 pA were 
loaded into the wells, reserving one well for SeeBlue Plus 20 molecular weight markers 
(5 l.tl). An electric field (150 V, 120 mA and 60 W) was applied to the gel for the time 
necessary for the dye front to reach the bottom of the gel (approximately I hour).The 
voltage was then removed and the polyacrylamide gel was stained in coomassie (Table 
2.3) approximately for 15 minutes and destained for at least 1 hour to remove excess of 
blue. Coomassie blue binds to the protein forming a blot, and the comparison between 
the positions of the blots with the markers give an indication about the presence of 
proteins and their size (figure 2.2). 
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Figure 2.2: Coomassie stained SDS-PAGE of the elution from the Nickel column. In the 
first lane there are size markers, while in the last one there is a sample of flow through 
from the washing step. The fractions with a predominant presence of nNOS 0, were 
collected. 
2.5.2 Enzyme Concentration 
Enzyme concentrations were determined spectrophotometrically exploiting the 
absorbance difference between the ferrous and the ferrous CO-binding forms being the 
extinction coefficient £444467 = 55, 000 M'cm' (118) (figure 2.3). Protein solution was 
diluted with gel filtration buffer to the volume of 1 ml in a 1 cm path length quartz 
cuvette and UV/vis spectra were recorded over the range 250 - 800 nm with a Shimadzu 
UV-2 101 PC spectrophotometer. Protein samples were reduced using sodium dithionite 
(Na2S204) and bubbled with CO to form the ferrous-CO complex and spectra were 
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(nm) 
Chapter 2: Material and Methods 
Figure 2.3: UV-Vis spectra of oxidised (black), reduced (red) and reduced CO-binding 
(blue) nNOS0  The spectrum resulted from subtracting the reduced one from the CU-
binding was used to calculate the enzyme concentration. 
CO-binding form and concentration were calculated according to the Beer-Lambert Law 
(A = Eel). 
2.6 Dissociation constants determination 
Difference spectrophotometry measurements were conducted to quantify the affinities of 
substrates, substrate-analogues and diatomic molecules. Optical spectra were recorded 
over the range of 250-800 nm using a UV-1601 Shimadzu spectrophotometer at 20°C. 
I ml solutions of nNOS o 1   were prepared in a quartz cuvette with a path length of 1 cm 
in gel filtration buffer supplemented with HB. Standard solutions of substrates and 
other compounds were prepared at high concentration in the same buffer and 
67 
Chapter 2: Material and Methods 
sequentially added having a final change in the sample volume of less than 5%. 
Manipulation of the spectra obtained was performed to determine the dissociation 
constants (Ki): from each spectrum corresponding to the enzyme partially bound to the 
substrate, the substrate-free enzyme spectrum was subtracted. In the resulting spectrum 
the difference absorbance between two evident peaks was determined, and the series of 
differences (&\Abs) plotted against substrate concentration. The wavelengths of the 
selected peaks varied depending on the ligands and on the enzyme used. The points 
were fitted to a Michaelis-Menten-like rectangular hyperbola and values of K,j were 
extrapolated (concentration of substrate at which half of the maximum concentration of 
the complex enzyme-substrate is observed) using Microcal Origin 7.0 software. In the 
cases, where in the first trial, the affinity of the compound appeared to be extremely 
high, accuracy in the method was increased using imidazole as a competitive heme 
ligand. In this way apparent Kds  for every compound were obtained: by using the 
imidazole concentration and its affinity for nNOS 0 , in the formula: Kd appre,,t = K1 
(l+[imidazole]/K), real Kds  were obtained. For the titrations of CO and NO affinity, 
their concentrations were worked out optically through the difference spectrum of 
CO/NO binding ferrous/ferric P450 BM3 (c 5=92.000 cm' and a41 =108.000 cm-1 
respectively). 
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2.7 OTTLE Potentiometric Titrations 
OTTLE (Optically Transparent Thin Layer Electrode) potentiometric measurements 
were performed at 25 °C using a Cary UV/vis spectrophotometer and Autolab 
PGSTAT1O potentiostat. All buffers and mediators used are shown in tables 2.7 and 2.8. 
Table 2.7: OTTLE Titration Buffers 
Buffer A 50niMTris 
500 mM KCI 
10% glycerol 
pH 7.5 
Buffer B 50 mM Tris 
500 mM KCI 
pH 7.5 
Buffer C 50 mM Tris 
500 mM KCI 
1 mM Laurate 
pH 7.5 
Prepared using MihiQ ultrapure water (of resistivity 18 Q cm') and pH adjusted using HCI 
Table 2.8: OTTLE Titration Mediators 
Mediator E (mV) vs SHE 
2-Hydroxy-1,4-Napthoquinone -145 
Flavin Mononucleotide -200 
Benzyl Viologen -310 
Met/n'! Viologen -430 
Prepared using MilliQ ultrapure water (of resistivity 18 Q cm') and pH adjusted using HCI 
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nNOS0 G586S midpoint potentials (E m) were calculated in the absence and presence of 
saturating concentrations of L-Arginine (10 mM). 
2.7.1 Sample Preparation 
All protein samples for OTTLE experiments were prepared in a Belle Technology glove 
box where 02 levels were maintained at < 5 ppm by nitrogen flow. The buffers used 
were previously degassed by nitrogen bubbling for at least 1 hour. Enzyme samples 
were degassed as well by introducing them into the anaerobic box at least 1 hour prior 
to use. 
L-Arginine Free G586S: A sample of concentrated pure enzyme was diluted to 100-150 
p.M in 0.5 ml of buffer A (table 2.7). Any remaining trace of oxygen was removed by 
running the sample down a G-25 gel-filtration column pre-equilibrated with buffer A: 
enzyme sample had then a volume of about I ml and concentration was 50-75 p.M. 
L-Arginine-bound G586S: The preparation of the enzyme solution was identical to that 
of substrate free enzyme, except for the presence of L-Arginme 10 mM in buffer A in all 
the steps where it was used. 
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Figure 2.8: OTTLE cell showing  a diagrammatic representation of the potentiostat 
and electrodes. 
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Figure 2.9: Panel A shows the changes in spectra observed during reduction and 
reoxidation of nNOS 0 . Inset shows the difference spectra {oxidised}-{reduced}. 
Panel B shows a current vs time plot for reduction and re-oxidation. Panel C shows a 
plot of proportion reduced vs applied potential and the le- Nernst plot fit for this data. 
Panel D shows the Nernst equation. 
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2.7.2 Mediators 
A range of mediators (Table 2.8) chosen according to their midpotential were added to 
the enzyme sample in order to facilitate electron transfer under the applied voltage. They 
were dissolved into the anaerobic box in degassed buffer A to a concentration of -2 MM 
and then added to the samples for a final concentration of-2 pM. 
2.7.3 Potentiometry 
The OTTLE experiments were conducted in modified quartz EPR cell with a path length 
of 0.3 mm provided with a Pt/Rh (95/5) gauze working electrode (wire diameter 0.06 
mm, mesh size 1024 cm', Engelhardt, UK), a platinum wire counter electrode and a 
Ag/AgC1 reference electrode (model MF2052, Bioanalytical Systems, IN 47906, USA). 
Enzyme samples were injected with a Hamilton 0.1 mm syringe into the lower and 
thinner part of the cell. The upper part of the cell was filled with OTTLE buffer B. The 
different content of glycerol (10 %) between the two buffers used prevented the mixing 
between the enzyme sample (glycerol) and the glycerol-free buffer at their interface. The 
cell was then sealed and located into a carry 50 Probe spectrophotometer out of the 
anaerobic box to monitor the changes in the spectra. The three electrodes were 
connected to an Autolab PGSTAT potentiostat and an initial potential more positive than 
the predicted enzyme mid-potential was applied through the working electrode. The 
applied potential was the lowered stepwise (50 mV) until complete reduction was 
observed and back to a completely oxidized form. The enzyme samples were allowed to 
equilibrate until no current was detected before a new potential was applied. Spectra 
were recorded for each applied potential and interpreted as the partition of the enzyme 
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into the two redox states. Difference spectra were calculated and plotted against applied 
potentials (corrected according to the standard hydrogen electrode (SHE), that is 
PotentialA5IcI + 205 m\'). Em  values, the potential at which the enzyme is equally 
distributed into the ferric and ferrous forms were determined by fitting the data to the 
Nernst equation (Microcal Origin 7.0) (Figure 2.9). 
2.8 Pre-Steady-State Kinetics 
Pre-steady-state kinetic measurements were all carried out at 10°C using an Applied-
Photophysics stopped-flow spectrophomoter (SX. I 7MV) connected with either a diode-
array or a single wavelength detector: diode array was used to monitor the absorbance 
changes on the entire UV-Vis spectrum while the single wavelength detector was used to 
measure faster processes once the optimal wavelength was found this having a smaller 
dead-time. The stopped flow apparatus was located into an anaerobic glovebox (Belle 
Technology; [02] < 5 ppm). Reagent concentrations and enzyme redox states were 
monitored by absorption spectroscopy on a Cary 50 Biospectrophotometer into the 
anaerobic box too. The general scheme for a stopped flow experiment was the 
monitoring of the oxy-ferrous complex formation by mixing ferrous enzyme and oxygen 
saturated buffer, and its decay. For all stopped-flow experiments the buffer used was Gel 
Filtration buffer (table 2.2) supplemented with 10 mM substrate (L-Arginine or NOHA) 
when needed. Buffer was made anaerobic by bubbling with nitrogen for 2 h before being 
left to equilibrate in the anaerobic box overnight. The 02 concentration in the oxygen 
containing buffer was measured exploiting the absorbance change caused by oxidation 
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of electrochemically reduced methyl viologen (eoo = 13,000 M'cm ') taking into 
consideration that each methyl viologen molecule donates 1 electron and that oxygen 
reduction to water requires 4 electrons. Typically, the final concentration of enzyme 
used for all pre-steady state kinetic experiments was 10 j.LM and saturating 
concentrations of substrates were 20 mM. Ferrous nNOSoxy was generated by a 
concentrated solution of sodium dithionite and verified spectrophotometrically. Sodium 
dithionite was brought into the anaerobic box in powder form and dissolved in anaerobic 
buffer. Excess reductant in the ferrous enzyme solution was removed by passage down a 
1.5 x 20-ml Sephadex G-25 (Sigma) size separation column immediately prior to use. 
Data were analyzed using Origin 7 (Microcal). Averaged traces from three or more 
measurements were used for analysis. 
2.9 Protein crystallization 
Crystallization of the G586S mutant for of NOS heme domain was carried out either by 
hanging drops or sitting drops vapour diffusion methods (126-128), using 24 wells 
Linbro® Plate and Cryschemrm plates, respectively (both from Hampton Research). 
Hanging drops (4 .tl volume) were prepared by adding 2 p.1 of 7-9 mg/mI protein (in 50 
mM pH 7.5 Tris / HC1, 0.2 M NaCl, 10 % glycerol, 1 mM dithiothreitol (DTT), 20 p.M 
114B to 2 ,d  of well solution. Crystals were obtained at room temperature with a well 
solution comprising 0.1 M MES pH 5.8 / 6.0, 22-24% PEG 3350, 0.2 M ammonium 
acetate, 25 MM L-Arg, 35 p.M SDS, 5 mM GSH, 2% isopropanol (all from Sigma). 
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Figure 2.10: Sitting drop (left) and hanging drop (right) crystallization methods 
NOS crystals needed to go through steps of mother liquor exchange with a cryo-
protected solution in order to not be damaged by the solvent change. Crystals were 
immersed in cryo-protectan solution stepwise (six steps) with an increasing amount of 
cryo-protectant. 
The cryo-protectant solution consisted of 0.1 M pH 5.8 / 6.0 MES, 25% PEG 3350, 100 
mM ammonium acetate, 10 % glygerol, 10% threaolose, 5% mannitole, 5% sucrose, 2% 
isopropanol and then flash cooled in liquid propane (130). 
Best dataset was collected (by C. Bruckmann) to 2.59 A resolution, at the European 
synchrotron radiation facility (ERSF) in Grenoble, France on beam line BMI4 using 
Mar Research charged camera detector (CCD) detector (wavelength 0.9737 A) at 100 K. 
Crystal were found to belong to space group P212 1 21 with cell dimensions a = 5 1.9630 b 
= 110.8470 c = 164.6270 c=J3=r  90. 
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Figure 2.11: Crystal snapshots. Beam line BM 14 
- 
Figure 2.12: Diffraction pattern of NOS G586S mutant crystal. Oscillation range 1.00, 
Exposure time 30.0 s; detector distance 269.4 mm; resolution at edge 2.5 A; resolution at 
corner 3.54 A. 
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Data processing was carried out (by C. Bruckmann) using MOSFLM (120) and SCALA 
(121). The structure was solved by molecular replacement using PFIASER (122) and the 
wild-type NOS structure (PDB entry 10M4), stripped of water, as a starting model. 
Electron fitting was carried out using the programs TURBO-FRODO (123) and COOT 
(124) and structure refinement was carried out using Refmac 5 (129) and Phenix(] 25). 
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3 CHARACTERIZATION OF G586S nNOS0 THROUGH UV/ VISIBLE 
SPECTROSCOPY AND LIGAND BINDING 
Amino acid residues in the distal portion of NOS heme domain are involved in the 
stabilisation and activation of the oxygen-heme complexes formed during NO 
production. The interactions they form with the transforming species have the task to 
promote oxygen binding, prevent uncoupled reactions and assist punctual 0-0 
bonding breakage. Inspection of the distal side of catalytic domain reveals a striking 
hydrophobic character of the residues which are placed to allow interactions during 
the reaction: surprisingly there are no residues capable of hydrogen-bonding which 
presence is expected in a reaction of this kind. The reaction performed by NOS is 
indeed similar to that performed by cytochrome P450, where hydrophilic residues 
play a key role during the activation of oxygen. An amino acid residue with the 
ability of forming hydrogen-bonds at a suitable distance from the space where 
substrate and oxygen-heme complexes interact may introduce species stabilization 
during the course of oxygen activation. With this in mind a mutant where the glycine 
586 was replaced by a serine residue (nNOS 0 G586S) was generated. The 
generation of a residue mutation in the heme proximity may alter the UV-Vis 
spectroscopic features of the mutant in a comparison with the wild type. Hence all 
the stabilized states in respect of their UV-Vis spectra were characterized, even in 
consideration of more complex analysis of the mutant, identifying each redox, 
substrates, ligands and cofactors-binding state of the enzyme. The way the mutation 
affects the binding of a variety of compounds, such as substrates, substrate-analogues 
and diatomic ligands, was tested and compared with that characterizing the wild 
type. 
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3.1 UVIVisibIe spectra 
As isolated, G586S nNOS0,, is in the oxidised (ferric) form and the visible spectrum 
has a broad Soret peak at 397 nm like the wild type enzyme (figure 3.1). The position 
and the broadness of the Soret peak were interpreted as indicating a mixture of high 
and low spin states in the sample. This was confirmed when the peak narrowed and 
moved to the left upon addition of L-Arginine, by indicating a shift to high-spin 
state. The Soret peak of G586S nNOS0 in this state is at 395 rim, as for the wild 
type enzyme (107). 
When L-Arginine-bound G586S was chemically reduced by Sodium Dithionite the 
Soret peak shifted to 413 nrn, similar to the ferrous wild type enzyme (figure 3.1). 
The enzyme obtained from purification was showed evidence of partial substrate 
binding, i.e. it was more high-spin than the wild type enzyme. In order to remove 
bound substrate the enzyme was dialysed overnight against a high concentration 
imidazole to displace the L-Arginine, and then several times in imidazole-free 
buffers to remove the imidazole: the imidazole-removing dialysis steps were 
repeated until no further changes were detected in the spectrum of the enzyme. 
Substrate-free G586S nNOS0 had a Soret peak at 400 rim. This compares to 398 nm 
for wild type nNOS. When chemical reduction was performed on substrate-free 
G586S nNOSOX), the Soret peak shifted from 400 to 410 nm as for the wild type 
nNOS0 (figure 3.1) (107). 
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Figure 3.1 UV-Visible spectra of G586S nNOS0  in different conditions of substrate 
binding and redox state. 
Imidazole binds to the NOS catalytic site (107, 108) by forming a complex directly 
with the heme, converting it to a low-spin form by competitively replacing the 
substrate and acting as sixth axial heme-ligand (figure 3.4). The binding of imidazole 
induces a shift in the Soret peak to 428 nm in wild type nNOS and for G586S 
nNOS0  to 426 nm indicating the same binding interaction. When ferrous G586S 
nNOS.xy  was bubbled with CO it formed a characteristic heme protein-CO complex 
with a Soret peak at 444 rim, as in wild type nNOS0 (figure 3.5). This was used to 
measure the enzyme concentration (see mat. & methods). 
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Figure 3.4 UV-Visible spectra of G586S nNOS0 imidazole-hound (orange), NO-
bound (green) and CO-bound (blue). 
In summary all the optical spectroscopic features of (i586S nNOS0 closely 
resemble those of the wild type enzyme, this indicates the absence of major structural 
rearrangement due to the mutation. 
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3.2 Affinity titrations 
The substitution of glycine 586 to a serine introduces a hydroxyl group directly into 
the active site. This may affect oxygen binding to the heme and its activation process 
during the reaction due to possible hydrogen bonding newly formed with the 
intermediates. Substrate binding also can be affected: the interactions with the amino 
acid residues into the wild type catalytic site are optimized in a way that both 
substrates have a similar affinity for the enzyme. The presence of a new hydroxyl 
group can introduce stabilizing hydrogen bonding but also create a different space 
limitation by the bulkier steric occupancy. Consequently there could be a newly 
introduced discrimination between L-arginine and NOHA way of binding. The same 
can be referred to the way the G586S nNOS0 , binds substrate-analogues and small 
diatomic ligands. Thus a series of affinities were measured and compared with those 
characterizing the wild type nNOS. 
3.2.1 Substrate aiThilty 
The space where the guanidinium group is located in the catalytic site could be 
described as being formed by two pockets, each hosting one amino group (figure 
3.6): the left pocket, viewing the ligand and the heme from above, is very tight and 
does not tolerate even the smallest substituent groups. The right-side pocket is 
slightly more spacious and is defined by the three residues Pro 565, Val 567 and Phe 
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Figure 3.6 Catalytic site of L-arginine bound nNOS: the pictures are taken from 
above the heme plane and from behind the a—carbon portion of the substrate 
(rotating the position of 900  around the x axis). The two corners hosting the two 
guanidinium amino groups are highlighted: on the left side of the allocation site the 
two residues Glu 587 and Trp 592 define a narrow space. On the right side Pro 565, 
Val 567 and Phe 584 limit a wider space that can tolerate bulkier groups (PDB file: 
10M4). 
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pocket always hosts the bulkier side of the guanidinium group (or of its substituted 
form) (figure 33). This is possible in all the cases where the analogues have at least a 
sm bond along the lateral chain (or what resembles it) of the arginine analogue: the 
free rotation around the axis of this bond allows the most comfortable position to be 
assumed. 
( 	





Figure 3.7 Stereoview of nNOS catalytic site binding vinyl-L-NIO. It is highlighted 
the corner formed by Pro 565, Val 567 and Phe 584 residues, hosting the intrusive 
vinyl group on the ligand (PDB file: 1MMW). 
The original 586 glycine residue is positioned in the right-side corner of the 
guanidinium group allocation (figure 3.8), and its mutation to a serine is highly 
probable to affect the spatial definition of this pocket. Although crystallographic 
evidence would be needed for a complete analysis, the affinity data collected were 
interpreted in consideration of the new shape assumed by this corner of the catalytic 
site. 
Difference spectrophotometry measurements were conducted to quantify substrates 
affinities. UV/Vis spectra of the enzymes were recorded prior and after each addition 
of high concentration substrate stock. From each spectrum corresponding to the 
enzyme partially bound to the substrate, the substrate-free enzyme spectrum was 
subtracted. In the resulting spectrum the difference absorbance between two evident 
peaks was determined, and the series of differences (&Abs) plotted against substrate 
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concentration. The points were fitted to a Michaelis-Menten-like rectangular 
hyperbola, 
y = ( AAbs Max *x)/( Kd+x), 
where y and x are the change of absorbance and substrate concentration respectively; 
values of Kd were extrapolated (concentration of substrate at which half of the 
maximum concentration of the complex enzyme-substrate is observed) using 
Microcal Origin 7.0 software. The method used to determine the binding affinity of 
nNOS0 for its ligands is graphically represented in figure 3.9. Even at a first glance 
it was clear that the G586S mutation had increased the affinity of the enzyme for L-
Arginine: as isolated from the purification, 0586S was in a mixed high-low spin 
state with a high-spin predominance in comparison to the isolated wild type enzyme. 
This most likely indicated a higher percentage of the enzyme being complexed with 
substrate due to the sequestering of L-Arginine from the cells and retained during 
purification. A first attempt to titrate the affinity of G586S for L-Arginine was made 
using the enzyme as isolated from the purification, exploiting the small shift to 
complete high-spin state upon substrate addition, as previously done with the wild 
type heme domain (107). The Kj values obtained were lower than those of wild type 
nNOS0 . 
In order to apply a hyperbolic ligand binding function, the L-Arginine concentration 
has to be in excess of that of the enzyme throughout the titration. If the Kd value is 
comparable with that of the enzyme concentration then the K d would be 
underestimated. Consequently the enzyme concentration needed to be low. On the 
other hand enzyme concentration cannot be too low otherwise the absorbance signal 
is too small to give detectable and reliable shifts upon substrate addition. 
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Figure 3.8 Catalytic site of L-arginine binding nNOS: the picture shows the 
proximity of the 586 glycine residue to the hosting site of the bulkier moiety of the 
guanidinium group. The mutation of this residue into a serine is highly probable to 
redefine the this corner of the catalytic site (PDB file: ILZX). 
To overcome this issue the titrations were conducted in the presence of imidazole 
which behaves as a competitive inhibitor for the active site binding with L-Arginine 
(116). The absorbance shift from the low spin-state of partial imidazole-occupied 
enzyme to that of high spin of substrate-binding enzyme was much more appreciable. 
The affinity of imidazole for G586S previously calculated by similar methods was 
then used to determine the K d according to the formula 
= K (1+[imidazole]/K1) 
where K is Kd for substrate binding and K 1 is K4j for imidazole binding. Titrations 
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Figure 3.9 Graphical representation of the method exploited to evaluate ligands 
binding constants to nNOSs: to a solution of the enzyme successive aliquots of the 
ligand were added and after an equilibration time a spectrum was recorded (panel a). 
From each spectrum was subtracted the ligand-free corresponding one: in the 
resulting difference-spectra (panel b) two clear peaks were identified and the 
absorbance difference between them measured. Each of these differences was plotted 
against the corresponding ligand-concentration and fitted to a rectangular hyperbole 
(panel c) and the K(j was calculated based directly on Michaelis—Menten equation 
were conducted in the presence of different concentrations of imidazole and the K 1s 
averaged. 
Data are graphically presented in figure 3.11. To confirm that imidazole behaves as a 
competitive inhibitor with L-arginine for the NOS active site, data corresponding to 
different concentrations of imidazole were manipulated and plotted according to the 
Lineweaver-Burk graphical representation (figure 3.10): the different x axis 
intercepts (indicating different apparent l(j)  joined to identical y axis intercepts of 
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Figure 3.10: Lineweaver-Burk graphs for imidazole competitive inhibition of G586S 
nNOSoxy in the presence of L-arginine (left) and NOHA (right). Circles, triangles 
and squares indicate imidazole 15, 10 and 5 j.tM respectively. 
In order to make comparison between the affinity constants of the mutant and wild 
type, those of the wild type were measured using the same method. The dissociation 
constants characterizing the binding of substrates to both wild type and G586S 





L-Arg 0.10±0.05 1.0±0.1 
NOHA 0.5±0.1 0.9±0.1 
hnidazole 235±4 86±2 
Table 3.1 Substrates and imidazole dissociation constants comparison for nNOS 
wild type and G586S. 
The Kd determined for the wild type heme domain for L-Arginine was in good 
agreement with that published previously (1 .tM) (107). The Kd for the binding of L-
Arginine to G586S nNOS0 was found to be 0.1 l.tM, indicating an increased 
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effectiveness of L-Arginine binding into the catalytic site. The comparison between 
the affinities of wild type and G586S nNOS0,, for NOHA showed also an increased 
affinity induced by the mutation: K js were 0.9 p.M and 0.5 JIM respectively. While, 
for the wild type enzyme both substrates bind with similar affinity, for the mutant L-
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Figure 3.11: Absorbance-difference titrations of substrates affinity. Left panel: wild 
type (.)and G586S (o)  nNOS0 , titrated with L-Arginine. Right panel: wild type (.) 
and of G586S (o) nNOS0 titrated with NOHA in the presence of 15 p.M imidazole. 
NOS concentration was 0.5 p.M. 
A possible explanation for the different action of the newly introduced serine residue 
should take in consideration not only hydrogen-bonding capacities, but space 
occupancy as well. In the crystallographic chapter it will be shown what is 
predictable by interpreting the affinity results: the 586 serine residue with its 
hydrogen-bonding capability must be positioned pointing towards the substrate. In 
particular, an interaction with the guanidinium group of the substrate seems likely 
from the effects of the mutation on substrates affinities. This position assumed by the 
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serine though, indicates its occupation of more space than in native 586 glycine. The 
mutation has an exclusively positive effect on L-Argimne binding, increasing its 
affinity 10-fold. Concerning NOHA, the modest increase in the affinity may derive 
from the larger size of the NOHA guanidinium group: the hydroxyl substituent group 
may be impeded by the serine hydroxyl and the negative effect of this interaction 
would decrease the positive effect of a serine H-bond. 
3.2.2 Substrate analogue affinities 
To further investigate the effects of the 586 serine introduction in the catalytic site, a 
series of substrate analogues (figure 3.11) were tested for their affinity to the G586S 
mutant and to wild type nNOS 0,,. The method used was the same as in the case of 
substrates affinity determination: the hyperbolic ligand binding functions 
corresponding to each titration are shown in figures 3.13 and 3.14. The common 
structural feature of the compounds tested was the resemblance of the overall L-
Arginine structure or the presence of portions of it. The dissociation constants for all 





Agmatine 42.8±5.7 130±23.5 
Amino Guanidine 546±70 1530±77 
L-NAME 31.7±2.0 7.9±3.3 
L-N1O 11.4±0.6 2.7±0.7 
Table 3.2 Substrate-analogues dissociation constants for nNOS 0 , and G586S 
nNOS0. 
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The structure of agmatine is identical to that of L-Arginine but for the absence of the 
carboxyl group on the cc-carbon (figure 3.12). Although sharing a very similar 
structure with L-Arginine, and particularly having a guanidinium group identical to 
that of the native substrate, its binding affinity is rather modest. It is in fact a 
competitive inhibitor of NOS with a K j of 130 p.M for the wild type enzyme. The 
average effectiveness of agmatine as a NOS inhibitor is possibly due to incorrect 
orientation. The mispositioning of the a carbon may result in a suboptimal 
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Figure 3.12: Substrate analogues of NO Synthase. 
with the key residues in the active site. Nevertheless when titrated with the G586S 
mutant, the affinity of agmatine was increased by a 3 fold, with a K 1 of 42.8 p.M. 
This suggest that the hydrogen-bonding capacity introduced with the serine mutation 
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The amino-guanidine structure resembles that of the guanidinium group of L-
Arginme: it is composed of a guanidinium group and a terminal amino group. Its 
inefficiency as a NOS inhibitor indicates how important the a-carbon-portion 
contacts are to achieving a position that maximizes binding. Its dissociation constant 
for wild type nNOS was calculated to be 1.53 mM. Even in this case of poor binding 
though, the affinity is increased again by 3 fold in the mutant. The interactions that 
are formed in the presence of serine 586 are offset the loss of a large portion of the 
molecule. In both cases, it appears that interactions formed between the guanidinium 
nitrogens, probably of an H-bonding nature, are able to increase the affinity of 
enzyme for analogue, possibly making it shift into a position closer to that of the 
native substrate. 
[Substrate Analogue] jiM 
Figure 3.13: Absorbance-difference titrations of substrate-analogues. Wild type (o) 
and G586S (.) nNOS with agrnatine. Wild type (() and G586S (c) with amino 
guanidine. The function K4's derived are in table 3.2. NOS concentration was 0.5 
tM. 
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The structure of L-NAME is like that of L-Arginine with a nitro group on one of the 
guanidinium nitrogens and an ester group on the a-carboxyl group. These 
substitutions make L-NAME a NOS inhibitor rather than a substrate. The binding 
constant for wild type nNOS has been calculated to be 7.9 tiM. The binding of L- 
NAME to the G586S mutant was characterized by a Kj of 31.7 gM, 4 fold lower 
than for the wild type enzyme. This decrease in affinity indicates that the newly 
introduced serine could clash with the terminal nitro group: this suggests that the 
serine points toward the nitro group of the modified guandinium group. As a 
consequence of the steric clashes H-bonding may not be possible between the 
oxygen of the nitro group and the hydrogen of serine 586. The overall result would 
be an unstable position for L-NAME in the active site of the mutant. 
0 	20 	40 	60 	80 	100 
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Figure 3.14 Absorbance-difference titrations of L-NAME and L-NTO. Wild type (C) 
and (3586S (o) nNOS with L-NAME. Wild type (o) and G586S (.)with L-NIO. The 
function Kj 's derived are in table 3.2. NOS concentration was 0.5 l.LM. 
Chapter 3: UV Visible Spectroscopy and Ligand Binding 
L-NTO is a powerful NOS inhibitor and it differs from L-Arginine in having a 
methyl group in place of one of the two guanidinium amino groups. Its efficiency as 
a wild type NOS inhibitor was characterized by a Kj of 2.7 tM. The affinity of L-
NIO for the 05865 mutant was characterized by a Kd of 11.4 M. Therefore the 
affinity was decreased by the serine mutation by more than 4 fold. As in the case of 
L-NAME, as the serine 586 is pointing towards the guanidinium group in the active 
site, it may clash with substituents on it. In this case there is no capability of H-
bonding between the serine and the terminal methyl, as the latter is not responsive to 
this kind of interaction. Overall binding is destabilized. 
3.2.3 Diatomic ligands affinity 
Small diatomic molecules such as NO and CO bind to the heme as sixth, distal 
ligands. NO binding to the heme is an important part of the catalytic cycle. Although 
with different affinities, it has the capability to bind both ferric and ferrous heme 
(62). Immediately after its production, NO stays bound to the ferric heme with 
micromolar affinity. NO is then released as part of a productive cycle. If another 
electron is delivered to the heme, producing ferrous iron, the enzyme is partitioned 
into a futile cycle, where the affinity of NO towards the reduced heme is very high, 
with a Kd in the nanomolar range, and from which it can be released only in the 
presence of oxygen in the form of NO3 (62). CO binding to the heme may not have 
such an important role during the normal functioning of NOS, but its exclusive 
binding to the ferrous form mimics that of oxygen (109). In fact the characterization 
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of both NO and CO binding to the heme in different conditions is important as 
source of information about the binding fashion of oxygen and the elements that 
regulate the reactivity of the much less stable oxy-heme complexes. We measured 
the affinities of NO and CO to the wild type and G586S mutant in the absence of 
substrate, in the presence of L-arginine and of NOHA. The graphic representation of 
the titrations data and the Michaelis-Menten-like function fittings are shown in figure 
3.17 and 3.18. 
Prior to each titration, buffer was bubbled with either NO or CO. The concentrations 
of the gases were measured with a spectrophotometer into the anaerobic box 
exploiting their high affinity for P450 BM3 and the peculiar peak formed upon 
heme-binding: the extinction coefficients are a4l8=108.000 cm' for NO/ferric-NOS 
and 5=92.000 cm-1 for CO/ferrous-NOS. UVIVis spectra of the enzymes were then 
recorded prior and after each addition of diatomic ligand containing stock. From each 
spectrum corresponding to the enzyme partially bound to the ligand, the non-bound 
enzyme spectrum was subtracted. In the resulting spectrum the difference absorbance 
between two evident peaks was determined, and the series of differences (MAbs) 
plotted against ligand concentration (figures 3.16 and 3.17). The points were fitted to 
a Michaelis-Menten-like rectangular hyperbola, 
y = (AAbs Max*x)/(  Kj+x), 
like for the substrate affinity titrations. 
NO binding measurements were possible only with the heme being in its ferric form: 
the affinity of NO for ferrous heme (nanomolar) (109) is too high to be determined 
with difference spectrophotometry techniques . The binding constant (Ks) of wild 
type nNOS0 in the absence of any substrate was calculated to be 2.5 .tM. The 
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affinity decreased when substrate was present, the Kd being 6.9 and 20.3 jiM in the 
presence of L-Arginine and NOHA respectively. This is in agreement with previous 
crystallographic results where the presence of L-Arginine and NO together in the 
active site causes a backshift of the substrate position and the bending of the Fe-N-O 
angle (109) (figure 3.15). 
Figure 3.15 Catalytic site of NO-binding nNOS in the presence of L-arginine. In the 
picture is highlighted the proximity between the guanidinium group of the substrate, 
NO and the 586 residue (PDB file: 206K). 
This is due to steric clashes and electrostatic interactions: when binding to the heme, 
NO can be considered as an electron donor, acquiring a positive charge (110), thus 
fonning a repulsive interaction with the positive guanidinium group of the substrate. 
On the other hand the affinity constants of NO calculated for the G586S mutant were 
not significantly affected by the presence of the substrates: Kds  were 1.8, 3.2 and 2.2 
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j.tM in the absence of substrate, in the presence of L-Arginine and in the presence of 
NOHA respectively. When binding, the CO donates one lone pair to the heme, 
causing it to acquire a slight positive charge. Furthermore the higher bond order 
between the atoms of the molecule make it bind in an almost linear fashion, with a 
very small tilt angle to the heme plane (109) (figure 3.16). 
Figure 3.16 Catalytic site of CO-binding nNOS in the presence of L-arginine. In the 
picture is clear how the guanidinium group of the substrate, CO and the 586 residue 
are at an interacting distance (PDB file: 2G6M). 
Not surprisingly, in wild type nN0S0 the binding of CO follows the same pattern 
of NO, being negatively affected by the presence of substrates. The anticooperative 
binding of CO and L-arginine due to the overlap between the nitrogen of the 
substrate guanidinium group and the diatomic ligand has been evidenced previously 
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(131, 132): this determines constraints that stretch the key enzyme-substrate 
interactions (e.g. the bidentate binding from the conserved glutamate). In the 
titrations conducted with the WT enzyme this effect was evident, although at a lower 
grade than expected. The K 3 of CO for the substrate-free enzyme is 10.4 p.M, while 
in the presence of L-Arginine and NOHA the Kds  are 21.4 and 30.8 pM respectively. 
It is remarkable that the binding of CO in the active site of G586S is promoted by the 
presence of both substrates. The K3 for the substrate-free mutant is 11.5 .tM, while 
in the presence of L-Arginine and NOHA it is 2.9 and 2.6 p.M respectively. These 
results (table 3.3), taken altogether indicate that the G586S mutation does not 
significantly alter the values of the constant binding for both NO and CO determined 
in the absence of substrate. There are, however differences between wt and mutant 
when the enzymes are complexed with substrate: generally the mutation increases 
the affinity for the ligand by factors 
Ferric nNOS0 Ferrous nNOS0 
NO NO NO CO CO CO 
No subs. L-Arg NOHA No subs. L-Arg NOHA 
G586S 
Kd (p.M) 1.8±0.1 3.2±0.2 2.2±0.2 11.5±1.5 2.9±0.3 2.6±0.2 
Wt 
K1 (p.M) 2.5±0.2 6.9±0.4 20.3±1.8 10.4±1.0 21.4±2.3 30.8±1.9 
Table 3.3 Affinities of NO and CO for both G586S and wild type nNOS in the 
substrate-free, L-arginine-binding and L-NOHA-binding enzyme. 
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ranging from 2-fold to 12-fold, indicating that a new interaction is formed by serine 
586 that requires the presence of the substrate in order to be formed. 
This stabilizing interaction may be due to a repositioning of the substrate caused by 
its interaction with 586 serine: as a consequence this may determine the formation of 
new positive interactions between heme binding molecules and the guanidinium-
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Figure 3.17: Difference-absorbance titrations of carbon monoxide binding to nNOS 
wild type in the absence (0) and presence of L-Arginine (.) and G586S in the 
absence (o) and presence of L-Arginine (.).NOS concentration was 0.5 tM. 
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Figure 3.18: Difference-absorbance titrations of nitric oxide binding to nNOS wild 
type in the absence (0) and presence of L-Arginine (.) and G586S in the absence (o) 
and presence of L-Arginine (.). NOS concentration was 0.5 p.M. 
substrate, the heme binding of oxygen during NOS reaction may be influenced in a 
similar manner: a faster formation of the oxyferrous compound during the reaction, 
and its stabilization once is formed may be detected when the enzyme reacts in the 
presence of substrate. 
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4 PRE-STADY-STATE KINETIC ANALYSIS 
4.1 Stopped flow experiments 
Stopped flow spectroscopy was used to study the heme redox-state transitions during 
reaction of both wild type and G586S nNOS0 with dioxygen in single turnover 
reactions. nNOS.,, y  was chemically reduced through the addition of Sodium Dithionite, 
and excess of reductant was removed through gel filtration in order to avoid interference 
in successive steps of the reaction. The ferrous enzyme was then mixed with 02-
containing buffer in a stopped-flow experiment. The reaction was monitored by 
identifying the different intermediates through their UV-Vis spectra, with both rapid-
scanning multiwavelength diode array and single wavelength detectors. The collected 
spectral data were then analyzed through software performing global analysis. The main 
intermediate observed in this reaction is usually the oxy-ferrous compound (Fe 11-02); the 
experiment follows its formation and its disappearance (figure 4.1), and the rates of both 
are determined. 
02 	
"2nd 	 -- 	 "decay 
Fe"-02 ) ' Fe" 
Figure 4.1 
For every step of the reaction the dependence on oxygen concentration was tested: 
when applicable, second order rate constants were derived by monitoring the reaction at 
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different oxygen concentrations. As the enzyme is active in a dimeric form, all the 
reactions were performed in the presence of pterin, either H 413 or 4-amino-I4*B (aH4B), 
which stabilize and promote the dimerization of the enzyme. The rate constants 
determined for the formation and decay of enzyme oxy-ferrous complexes in a variety of 
conditions are in table 4.1. Although most of the stopped flow experiments in different 
conditions with wild type nNOS 0  were performed during the project, some data from a 
previous work has also been included as referenced (63). 
Oxy-ferrous 
formation k2nd 
(JIM F'  s') 
Oxy-ferrous decay 
kiecay (s) 
G586S/H4B/Arginine 2.8±0.2 16±2 1.2±0.1 
wt/H 4B/Arginine 1.1±0.1 17±2.0 
G586S/H4B/NOHA 3.1±0.2 15±2 1.0±0.1 
wt/H4BINOHA 1.1±0.1 4.9±0.5 	(63) 
G586S/aH4B/Arginine 1.4±0.1 0.20±0.02 
wt/aH 4B/Arginine 1.2±0.1 0.06±0.01 	(63) 
G586S/H48 0.10±0.01 - 
wt/114B 0.46±0.10 >160±13 	(63) 
G586S/aH4B 0.14±0.01 - 
wtIaH4B 0.47±0.04 8.3±0.9 	(63) 
Table 4.1 Rate constants for the oxy-ferrous formation (left) and decay (right, either in 
one or two steps) determined in a variety of conditions. 
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4.2 Substrate-free nNOS0 ,, 
When the ferrous wild type nNOS complexed with R 1B and with no substrate was 
mixed with the oxygen, the starting Soret peak at 410 simply broadened towards shorter 
wavelengths (63); contemporarily, the ferrous-heme characteristic peak in the 
a-3 region was replaced by the two ferric-type peaks. There was no sign of oxyferrous 
species formation, but a direct increase of the ferric-form population of the enzyme. The 
decays were fitted to single exponential functions and the rates observed showed a linear 
dependence on the oxygen concentrations tested. These results were interpreted as an 
extremely fast decay of the newly formed oxyferrous species occurring: its rate differs 
so much from that of the formation (being faster) that there is no detectable 
accumulation of the oxyferrous compound (figure 4.2). The rates observed through the 
fitting of the traces are then those of the formation step, which being much slower than 
the decay is the limiting step. Plotting them against the oxygen concentrations, the 
authors determined a second order rate constant for the formation process of 0.46 j.tM' 
s- ' (63). 
IRJO 	 FelI..02 	 44. 
Limiting 	 Very Fast electron 
Process donation from H 4B 
(k2fld= 0 . 46  mM 1 s 1 ) 
Figure 4.2 
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When the stopped flow experiment was repeated with enzyme purified in the presence of 
amino-H413 in the absence of any substrate, the detected path of the reaction was 
different. 
Amino-(6R)-5,6,7,8-tetrahydro-L-biopterifl (amino-1-LB) (figure 4.3) is a useful tool in 
the analysis of the NOS catalytic cycle. It is an analogue of 11 413, with an amino group 












Figure 43: I-T4B and amino-114B pictured in the forms with which they bind into the 
catalytic site of the enzyme. 
It binds to the enzyme with a 20-fold higher affinity compared with I-L 4B (111), and the 
position assumed in its binding site is virtually undistinguishable from that of the 
physiological pterin (fig. 4.4). 
The widely accepted reason for amino-I1 4B inhibiting NOS is its inability to perform the 
second electron donation. The redox properties of amino-H 4B tested in solution are 
similar to those of H413, being the potential of the latter is only 60 mV more negative: 
this difference is too small to justify the inability to donate an electron. An important 
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aspect to be considered analyzing the different behaviour of the two pterins is the 
tautomeric form with which they bind the enzyme: H 4B is found exclusively in the form 
where the oxygen on the C4 is bound with a double bond (4.4). This form corresponds to 
that of the imino tautomer of amino-11 4B, which, on the other hand, binds preferentially 
to the enzyme in its amino tautomer. As a consequence, in amino-H 413 the N3, to keep 
on forming the hydrogen bond with the heme propionate needs to be protonated (such is 
that of I-LB), and as a result is positively charged. The charge on amino-H 4B is thought 
to stabilize the tetrahydro form, disfavouring the formation of the radical upon one 
electron donation (111). 
Figure 4.4: Overlaid structures of fl4B (mainly yellow) and amino-114B (mainly light 
blue). The two pterins assume position virtually identical into the catalytic site. 
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However it has also been proposed that the inhibition of NOS by amino-11 4B is due to its 
inability to donate a proton, rather than an electron (115): this hypothesis was based on 
the EPR detection of the radical form of amino-H4B during NOS turnover in the 
presence of L-arginine, very similar to that formed by H 4B. The lack of NO production 
was then justified by proposing that the amino group substituent stabilizes the pterin 
structure in a way that impedes the proton donation to the electron activated (by amino 
H4B itself) oxyferrous compound. Given that amino-11 4B binds in a cationic form, this is 
unlikely. 
As said, when the stopped flow experiment was performed with wild type enzyme 
purified in the presence of amino-I-14B in the absence of substrate, the detected path of 
the reaction was different from that in the presence of H 413 (figure 4.5). 
02 
Fell 	 Fell 0 
Same rate as in the Slowed by the lack 
presence of H4B 	 of electron donation 
(k2fld 0.47 mM-1 s-1 ) 
Figure 4.5 
Upon mixing with oxygen the ferrous Soret peak shifted to 419 nm, demonstrating the 
formation and accumulation of an oxyferrous compound. This step was linearly 
dependent on the oxygen concentration and the second order rate constant was virtually 
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shifted to that characteristic of the ferric enzyme at 395 run, in a slow and oxygen 
independent manner. The traces were fitted to single exponential equations and the rate 
determined to be 8.3 s. The comparison between the two stopped flow experiments 
conducted in the presence of the different pterins, confirmed the role of 114B as an 
activator of the oxyferrous compound by donation of one electron. Amino-H 413 on the 
other hand, doesn't influence the 2d  order rate constant for formation of the oxyferrous 
species, but delays its decay by not donating the activating second electron. The decay 
proceeds more slowly by release of superoxide (02). 
When the stopped flow experiment was performed with the G586S mutant in the 
absence of any substrate complexed with either fl413 or amino-144B the 





G586S/H 4 B/nosub 
Figure 4.6: The spectrophotometric pattern of the substrate-free mutant reaction, either 
in the presence of I-L 113 or amino-11413 is very similar: it evidences a hint of the 
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Two phases were distinguishable: in the first milliseconds there was a quick shift of the 
Soret peak from 410 to 416 run, accounting for a subpopulation of the ferrous enzyme 
forming the oxy-ferrous compound. Subsequently the peak broadens, and slightly shifts 
to lower wavelength on a time scale of seconds The Soret peak never reaches at 395 nm 
that characterizes the high spin ferric enzyme, but stops at 405 nm indicating low spin 
ferric nNOS0, (formed in the absence of substrate). This transition, reflecting the decay 
of the oxy-ferrous compound (figure 4.7) is oxygen concentration dependent and shows 
no evidence of 
2 	 4 	0 	 Z 
Time (s) 	 Time (s) 
Figure 4.7: Decay traces for the substrate-free G586S nNOS0 in the presence of 
amino-11413 (left) and 114B (right). 
saturation in our range of concentrations. 
The interpretation of the reaction is not simple, for the spectral transition is not 
completely defined. As in the wild type enzyme in the absence of substrate and 1-L4B-
bound, in the cases here discussed it is possible to calculate the second order rate 
constant for the oxyferrous species formation by plotting the rates of decay observed 
against the corresponding oxygen concentrations: very similar values were obtained, the 
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rate constant for the oxyferrous formation in the presence of HB 0.10 11M' s', and that 
in the presence of amino-114B 0.14 jiM' s'. A possible explanation of the 
transformations occurring in both cases involves a very slow formation of the oxyferrous 
compound such that the accumulation (if any) is just partial, due to the much higher rate 
of decay of the oxyferrous species. The comparison between the second order rate 
constants for oxyferrous formation in both wild type and (3586S nNOS0 , in the 
presence of either 11 413 and amino-14413 is shown in table 4.2: the values indicate a slow 
oxyferrous formation step in the absence of substrate, and consequently an overall poor 
oxygen affinity. In the mutant the affinity for oxygen is lower than that of the wild type 
with no substrate present. The diatomic ligand binding stabilizing effect detected in the 






G586S/H4B 0.10±0.01 - 
wtJH4B 0.46±0.10 >160±13 
G586SIaII4B 0.14±0.01 - 
wtJaH4B 0.47±0.04 8.3±0.9 
Table 4.2 Rate constants for the oxy-ferrous formation (left) and decay (right) 
determined in the absence of substrate and in the presence of either I -LB or aH4B in the 
G586S and WT nNOS 0,,. 
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It can be inferred then that the stabilizing effect introduced by the serine 586 mutation is 
exerted through the substrate, rather than through a direct interaction with the bound 
oxygen; it is also possible that a negative effect on ligand binding in the mutant may be 
due to the bulkier space occupied by the hydroxyl group pointing to the heme, or the 
ordering of water molecules in the active-site pocket. 
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4.3 Wild type nNOS..y  in the presence of substrate and H413 
When wild type nN0S 0 , in its ferrous form was mixed with oxygen-containing buffer in 
the presence of L-arginine and 114B, the UV-Vis Soret peak at 410 nm shifted to 429 nm 1 
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Figure 4.8: Diode array spectra for stopped flow reaction of wild type nN0S 0, with 02 
in the presence of L-arginine and 11 4B. Absorbance spectra of the enzyme species are 
ferrous (red), oxyferrous (orange) and ferric (black). 
The Soret peak of the enzyme then shifted to 395 nm, the position of the high spin ferric 
heme. In order to understand the overall process, the spectral data were analyzed through 
the global analysis software provided with the stopped flow apparatus. A two-step model 
corresponding to oxyferrous complex formation and decay was used: 
A--B—C 
Also, the three accumulating species spectra characterizing the reaction were 
extrapolated by the software: these were identified to be the starting ferrous enzyme (A), 
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the oxyferrous species (B) and the eventually formed resting ferric enzyme (C) (figure 
4.9). 
The overall process was in good accordance with what was observed previously in a 
study focusing on wild type nNOS 0  (63): the oxyferrous compound is the last species 
identified during the reaction, before the ferric resting state complexed with the newly 
formed product, NOHA is observed. Although the global analysis provided the rates for 
each step, for greater accuracy both formation and decay of the oxyferrous compound 
were followed at single wavelength: at 419 and 398 nm respectively, it was possible to 
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Figure 4.9: UV-Visible spectra of accumulating species determined by global analysis 
of WT+substrate vs. 02 data: ferrous enzyme (red), oxyferrous species (orange) and 
ferric enzyme (black). 
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Figure 4.10: Oxyferrous species formation in the wild type enzyme with L-arginine. 
Traces were followed at 419 nm (a) and k plotted against oxygen concentrations to 









Figure 4.11: Oxyferrous species decay followed at 398 run. 
using the single wavelength spectral change recorded at 390 nm, to fit the trace to a 
double exponential equation that summarizes the reaction (figure 4.12). The formation 
of the oxyferrous compound showed a dependence on oxygen concentration: when the 
kobs were plotted against the oxygen concentration, the second order rate constant was 
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Figure 4.12: Absorbance change at 390 nm during wild type reaction representing both 
quick oxyferrous formation and slow decay. Fitted to a double exponential equation. 
calculated to be 1.1 j.1M's 1 . The decay transition occurred in an oxygen concentration 
independent manner, with a rate constant of 17 sI. 
Global analysis of the spectral data allowed also the plotting of the timecourse of the 
overall reaction concerning the concentration of the species (figure 4.13). 
When the NOS reaction was triggered by mixing with oxygenated buffer in the presence 
of NOHA as substrate, the UV-Vis spectrum changed in a similar way. Oxyferrous 
compound formation was detected by the Soret peak shifting from 410 to 429 nm. Also 
in this case the formation showed dependence on oxygen concentration, and the second 
order rate constant for this process was virtually identical to that in the presence of L-
Arginine: 1.1 tM' s 1 . The decay of the oxyferrous species was in these conditions 
somewhat slower, the rate constant being 4.5 Also in this case the traces recorded at 
single wavelength were fitted to single exponential functions: hence at least one of the 
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- 	 Ferrous 
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Figure 4.13: Concentration timecourses of the intermediates during the reaction of the 
wild type nN0S0 Y with 02 in the presence of L-Arg and F11B. The plot was elaborated 
by global analysis of raw data shown on figure 4.6. 
steps of the unknown part of the reaction slows down the overall process of decay of the 
oxyferrous species. There is no spectral evidence of NO-bound enzyme or of NO release 
from the heme: presumably this step is too fast to be observed (62). 
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4.4 G586S nNOS0 , 3, in the presence of L-arginine and H 4B 
When reduced G586S mutant with L-arginine and I-LB bound was mixed with oxygen., 
formation of the oxyferrous compound was evident by the shift of the Soret peak from 
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Figure 4.14 : Diode array spectra showing stopped flow reaction of G586S nNOS0 
with 02 in the presence of L-arginine and 114B: the ferrous enzyme (red) binds oxygen 
forming the oxyferrous species (orange), which decays in two phases through 
accumulation of a new intermediate (green), and to ferric enzyme (black). 
Once formed in the mutant, the oxyferrous species faced a different fate compared with 
the wild type species: the main difference at a first glance was a slower overall decay to 
ferric form than in the same conditions in the wild type enzyme. Also, a difference in the 
sequence spectra detected was noticeable. To make sense of the overall reaction, global 
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analysis was conducted on the spectral data. The two-steps model used for the wild type 
enzyme did not fit the spectral changes. A three-steps model, 
A--B---'C—'D 
fitted the process successfully. This elaboration allowed the identification of four 
spectral species transforming one into the other (figure 4.15): the ferrous enzyme (A), as 
already said, reacts with oxygen to form the oxyferrous compound (B). The latter then, 
during the first phase of its decay, forms a species (C) not easily identifiable by its 
spectrum, the maximum peak at 423 nm being extremely broad and lower. Furthermore 
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Figure 4.15: Accumulating species sequence elaborated by global analysis in the G586S 
reaction with L-arginine and ILB: ferrous enzyme (red), oxyferrous species (orange) 
new intermediate (green) and ferric enzyme (black). 
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the bump peculiar of the ferrous state of the enzyme: the signal is somewhat evenly 
flattened. 
The newly detected intermediate decayed then in a second phase to the ferric form in a 
slow manner. The rates of each step of the process were provided by the fitting of the 
spectral data to a A—*B--*C—D model, but for greater accuracy they were determined 
through single wavelength trace fitting. As with wild type enzyme the oxyferrous 
formation process showed dependence on the oxygen concentration and its second order 
rate constant was calculated to be 2.8 tM' s'(flg. 4.16): the mutation of the 586 glycine 
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Figure 4.16: Oxyferrous species formation in the G586S enzyme. Traces were followed 
at 417 nm (a) and kjs plotted against oxygen concentrations to calculate graphically the 
second order rate constant of the oxyferrous formation (b). 
the ferrous heme in comparison with the wild type enzyme. The first phase of decay 
showed no dependence on oxygen concentration and its rate constant was measured to 
be 16.0 s ' (fig. 4.17). The newly detected intermediate decayed to the ferric form at 1.2 
S_ 
I  and was also independent of oxygen concentration (fig. 4.18). 
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Figure 4.17: Oxyferrous species first phase of decay followed at 427 nm. Fitted to a 
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Figure 4.18: Eventual decay to ferric enzyme of the newly stabilized intermediate 
followed at 408 inn (fitted to a single exponential equation). In the trace is also evident 
the oxyferrous formation phase. 
The normalized concentration timecourse of the intermediates forming during the 
overall reaction are shown in figure 4.19. 
122 













0.0 	0.2 	0.4 	0.6 
Time (s) 
Figure 4.19: Concentration timecourses of the intermediates during the reaction of the 
G586S mutant with 02 in the presence of L-Arg and 11 4B. The plot was elaborated by 
global analysis of raw data shown on figure 4.4. 
When the mutant complexed with 114B was provided with NOHA as substrate in place 
of arginine, the overall pathway of the reaction didn't change. The oxyferrous compound 
formation had a second order rate constant of 3.1 xM' s. The first phase of decay rate 
constant was measured to be 15.0 s'. The second and final decay to ferric enzyme had a 
rate ofl.Os'. 
From the results presented (the rates of the reactions with both enzymes in the presence 
of substrate are in table 4.3) it is clear that the newly introduced serine influences the 










wt/H4B/Arginine 1.1±0.1 17±2.0 
G586S/H4B/Arginine 2.8±0.2 16±2 1.2±0.1 
wt/H4B/NOHA 1.1±0.1 4.9±0.5 
6586S/H4BINOIIA 3.1±0.2 15±2 1.0±0.1 
Table 4.3 Rate constants for the oxy-ferrous formation (left) and decay (right, either in 
one or two steps) determined in the presence of substrate and in the presence of 114B  in 
the %VT and G586S nNOS0 .. 
The contribution is likely to be based on a newly formed hydrogen-bond interaction. As 
shown by the affinity comparisons between the wild type and the G586S mutant (chapter 
3) the mutated serine must be directed towards the space where the substrate is located 
over the heme plane. This will be confirmed by the structure of the G586S mutant in the 
presence of L-arginine (chapter 6). Particularly, it can be inferred that the interactions 
modifying the affinity of the substrates and substrate-analogues must involve the 
guanidiniutn group of the ligand (or its modified form) and the lateral chain of the serine 
586. The interaction of this residue with the heme-substrate-oxygen species occurs 
during the course of the reaction. A comparison between the catalytic results obtained 
with both enzymes in the presence and absence of substrate, supports the theory that the 
new stabilizing interaction in the catalytic site is exerted through a direct interaction 
between the substrate and the mutated residue. 
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4.5 Analysis of the nature of the newly stabilized intermediate 
Stopped-flow analysis of the G586S mutant complexed with ammo-I-14B in the presence 
of L-arginine is shown in figures 4.20 and 4.21. The reaction follows a pattern similar to 
amino-H4B bound wild type nNOS in the same conditions (63): it shows a first step of 
oxyferrous formation which is oxygen-concentration dependent and characterized by a 
second order rate constant of 1.4 iM's'. The decay to the ferric heme occurs via a 
single step in an oxygen-independent manner, but is much slower than that occurring in 
the 114B and arginine bound enzyme, at 0.2 sI.  In the same conditions, the wild-type 
enzyme's oxyferrous formation is characterized by a second order rate constant of 
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Figure 4.20: Stopped flow reaction of G5865 nNOS0 with 02 in the presence of L-
arginine and amino-1-14B: the enzyme species are ferrous (red), oxyferrous (orange) and 
ferric (black). 
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transition also occurs in a single slow step with a first order rate constant of 0.06 s 1 , i.e. 
slightly slower than that of the mutant. 
The fact that the new intermediate is not detected when substrate-bound G586S nNOSO, ), 
reacts in the presence of amino-FI4B, points to how its formation relies on the second 









Figure 4.21: Absorbance change trace at 398 nm during G586S nNOS0 reaction in the 
presence of L-arginine and amino-I-1 413. The fast formation and slow decay processes are 
evident. 
Thus the newly stabilized intermediate is possibly a species involved normally in the 
catalytic cycle and must be an intermediate formed after the oxyferrous complex. In the 
attempt to define the identity of the new intermediate, similar features in the spectra of 
reaction intermediates of heme proteins which perform oxygenase reactions were 
researched. Similarities were found with the spectrum of the second intermediate 
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deriving from the reaction of low spin ferric P450cam with m-chloroperbenzoic acid 
(112). Characteristics of this species include the presence of a broad Soret band at 370 
rim and a weak band at 695 nm. Egawa et al. achieved a clean spectrum of 
chioroperoxidase Compound I through mathematical elaboration, which was previously 
isolated and recognized in the peroxidase reaction. Successive studies confirmed the 
identity of this spectrum (113, 114) (figure 4.22). Although the intermediate identified in 
the reaction performed by 
Figure 4.22: Time-resolved UV-vis spectrum for reaction of chloroperoxidase 
Compound I (lower green spectrum) with the substrate (styrene) (113). 
the glycine 586 mutant is not identical, there are some features that suggest that it could 
represent a mixture of the oxyferryl compound and other transients: first, there is a 
lowering and broadening of the peak during the step that leads from the oxyferrous 
compound to this new transient; second, the big shoulder at around 370 rim is evidence 
of the strong presence of a species with an absorption peak at that wavelength; third, 
during this step some flattening in the oL/P region occurs, which tells us about the 
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presence of a species which is neither ferrous nor ferric. The characteristic small peak of 
compound I at around 695 rim is also in evidence by an increase in absorbance in this 
region. 
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5 ELECTROCHEMISTRY 
5.1 nNOS0, G586S reduction potentials 
In order to assess whether the mutation affects the reduction potential of the G586S 
mutant, potentiometric titrations were conducted in the presence and absence of the 
substrate. The ferric enzyme kept in its dimeric form by the presence of l-LB, was 
reduced and then oxidised stepwise in an anaerobic O1TLE cell by modulating the 
potential of the working electrode; after each potential change the enzyme solution 
was allowed to equilibrate and the UV-Visible absorption spectrum was recorded. At 
each applied potential, positions of the Soret peak shifting from those of the ferric and 
ferrous states (figure 5.1) were interpreted as the statistical distribution of the enzyme 
into the two reduction states. 
Potentials (mV 




















Figure 5.1: Spectra of the G586S enzyme in the presence of L-arginine shifting 
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Figure 5.2: Spectra of the G586S enzyme in the absence of L-arginine shifting 
between a fully oxidised and a fully reduced population upon applied electric 
potentials. 
The absorbance change (figure 5.2), after being normalized was then plotted against 
the applied potential and the curve fitted to the Nernst equation, 
E = 	




The plots are showed in figure 5.3: the value of the applied potential at the midpoint, 
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Figure 5.3: Series of difference spectra corresponding to each applied potential in the 
presence of L-arginine-complexed enzyme. 
During the determination of the heme potential of substrate-free NOSOX Y , hysteresis 
was observed, in that the curves obtained going from ferric to ferrous states and back 
don't overlap exactly. More precisely a portion of the enzyme retains its reduction 
state regardless of the change in the electric field applied: consequently the 
distribution of the enzyme population into the two different oxidation states doesn't 
rely exclusively on the absolute value of the electric field applied, but on the direction 
of the changes as well. This effect may be connected with the lack of structural 
stability caused by the absence of L-arginine in the catalytic site. Nevertheless a 
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Figure 5.4: Series of difference spectra corresponding to each applied potential in the 







Figure 5.5: Nernst curves for the potentiometric titration of the G586S enzyme in the 
presence (a) and in the absence (b) of L-argimne. 
In the first step of the P450 reaction, the binding of substrate commonly displaces a 
loosely bound molecule of water acting as the sixth iron ligand (52, 88, 89). 
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No substrate L-Arg 
G586S (mV) -329±8 -318±4 
Wt (MV) -316±5 (63) -306±4(63) 
Table 5.1: nNOS0 wild type and G586S reduction potentials in the presence and 
absence of L-Arginine. 
This has a destabilizing effect on the ferric form of the enzyme. Substrate binding has 
been measured to cause a heme reduction potential shift of about +lOOmV (i.e. P450 
BM3) (117), directing the enzyme into a state where the first electron transfer that 
triggers the entire reaction is considerably more favourable. This mechanism helps to 
prevent uncoupled hydride consumption in the substrate-free enzyme. The heme 
reduction-potential shift induced by substrate binding in wild type nNOS0 doesn't 
result in a similar uncoupling-preventing mechanism (63): the preferential binding of 
L-arginine to the ferrous form of nNOS has been causes a potential shift of about 10 
mV. This is a relatively small difference. 
The midpotential measured for the G586S nNOS0 mutant in the absence of any 
substrate is -329 mV, while the potential measured in the presence of L-arginine is - 
318 mV. The positive 11 mV shift in the heme potential is due to the preferential 
binding of the substrate to the reduced form of the enzyme. Although the 
corresponding midpotential values of the G586S NOSO XY are some 10 mV more 
negative than those of the wild type, the potential shift determined in the latter by the 
presence of L-arginine (10 mV) is virtually the same (63). This is consistent with the 
G586S mutant enzyme retaining the heme native electrical properties. 
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6 CRYSTALLOGRAPHIC STUDIES ON RAT G586S nNOSoxy  
(in collaboration with Chiara Bruckmann) 
In order to interpret the spectroscopic, catalytic and electrochemical studies of 
G586S nNOS01  in terms of structural information, the enzyme was crystallised in 
the presence of L-arginine and H4B. Its structure was determined using X-ray 
crystallography by C. Bruckmann. 
6.1 Purification 
The G586S mutant of nNOS0,, was successively expressed and purified as 
previously described (63). In order to obtain a purer enzyme, necessary for 
crystallographic studies, the purification protocol followed previously was modified 
according to that followed by Li et al. (109). 
Cell homogenate containing over expressed nNOS, G586S mutant was loaded into 
a HisTrap HIP column (GE Healthcare), previously equilibrated with 50 mM sodium 
phosphate buffer at pH 7.8 containing 10% glycerol, 1 mM dithiothreitol (Dli'), 20 
pM H4B, 0.1 mM L-argrnme, 0.3 M NaCl, and 20 mM imidazole (equilibration 
buffer). After a thorough washing step with equilibration buffer (5 column volumes) 
the protein was eluted from the HisTrap HP column using a 100-150 mM imidazole 
step gradient (figure 6.1) generated mixing volumes of two equilibration buffer 
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mw(kDa) 
Figure 6.1: Abs280 trace (blue) from HisTrap HP purification and elution gradient 
trace (green) (a). The corresponding fractions of the peak were analysed by SDS-
PAGE (b). 
The colored elution peak fractions were pooled together and dialyzed overnight at 
4°C against buffer 1 (HEPES 50 mM pH 7.5, 10% glycerol, 1 mM DTI', 20 j.tM 
14413, 0.1 MM L-Arg and 0.25 mM PMSF). 
Post-dialysis fractions from HisTrap HP were loaded onto a buffer 1 pre-equilibrated 
(5 column volumes) HlTrapQ FF anion-exchange column. The column was then 
washed with 2 column volumes of buffer I containing 100 mM NaCI. The protein 
was eventually eluted with a 100— 300 mM NaCl gradient using 10 column volumes 
(figure 6.2). 
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Figure 6.2: The elution profile from ion exchange chromatography using a FllTrapQ 
FF column (a). Abs280 trace is represented in blue and elution gradient trace in green. 
The target enzyme peak can be seen on the elution profile and the corresponding 
fractions were analysed by SDS-PAGE (b) 
Neuronal NOSOXY has an N-terminal PDZ domain, which is a portion essential for the 
interaction with other proteins (mainly for localization): this is composed of a 6-
stranded anti-parallel n-barrel and 2 a-helices (11) (figure 6.3a). Due to its high 
mobility the PDZ-domain hinders the crystallization of the protein and no structure 
of nNOS PDZ-domain including sequence has been solved so far. The cleavage of 
the mobile domain was achieved by a limited trypsin digestion of the protein 
collected after the Q-Trap column step. 
The reaction was carried out by incubating the protein solution on ice overnight with 
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The results of partial trypsin proteolysis were analyzed by SDS-PAGE and if 
necessary the digestion was continued. Undigested enzyme was used as a control 
(figure 6.3b): the successful cleavage was detected by molecular weights 
a 
Figure 63: a) Illustration of the trypsin digestion of nNOS 0,,, where the PDZ 
domain is cleaved from the heme domain. b) SDS-PAGE comparative analysis of 
the trypsin digestion product (2) with the undigested protein (1). 
comparison between the digested and undigested enzyme, considering that the PDZ 
domain has a mass of 15 kDa. 
In order to remove undigested enzyme, the trypsin-treated NOSO XY solution was 
further purified through a Superdex 200 column equilibrated with 50 mM TrisHCl, 
pH 7.8, containing 10% glycerol, 10 mM Dli', 20 pM H4B, 0.1 mM L-Arg, and 200 
mM NaCl (figure 6.4). The protein eluted at a volume corresponding to - 50 kDa 
molecular weight. 
Protein concentration was determined spectrophotometrically exploiting the 
absorbance difference between the ferrous and the ferrous CO-bound forms 
(extinction coefficient = 55, 000 M'cm') (118). 
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Figure 6.4: The elution profile from gel-filtration chromatography using a Superdex-
200 10/30 column for nNOS0 G586S mutant (blue) overlaid with the elution profile 
of the molecular weight markers (cyan). 
6.2 Crystallization (by D.Papale and C. Bruckmann) 
Crystals of the G586S mutant of nNOS heme domain were produced by the hanging-
drop or sitting-drop vapour diffusion methods at 18°C, by mixing 2 p.1 of 7-9 mg/ml 
protein (in 50 mM TrisHCl, pH 7.8, 10% glycerol, 10 mM DF, 20 p.M 1-1 413, 0.1 
MM L-Arg, and 200 mM NaCl) with 2 p.1 of reservoir solution (0.1 M pH 5.8/6.0 
MES, 22-24% PEG 3350, 0.2 M ammonium acetate, 25 mM L-Arg, 35 p.M sodium 
dodecyl sulfate (SDS), 5 mM glutathione (GSH), 2% isopropanol). 
Small crystals appear after 24 h (rod shape) and reached maximum size in 1 week 
(figure 6.5). 
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Figure 6.5: Crystals of G586S nNOSOX )f grown in a 4 p.1 volume sitting drop 
6.3 Freezing procedure (by C. Bruckmann) 
Crystals of G586S nNOS0 were washed with reservoir solution and then exposed to 
increasing amounts of cryoprotectant in a step-wise fashion. The final cryoprotectant 
solution consisted of 25% (w/v) PEG 3350, 0.1 M MES, pH 5.8/6.0, 0.1 M 
ammonium acetate, 10% (v/v) glycerol, 10% (w/v) trehalose, 5% (w/v) sucrose, 5% 
(w/v) mannitol and 1 mM L-Arg (119). Crystals were flash-cooled in liquid propane. 
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6.4 Data collection (by C. Bruckmann) 
The best dataset was collected to 2.59 A resolution at 100 K at the ERSF (Grenoble, 






Figure 6.6: a) Crystal snapshots on beam line BM14, ESRF. b) Diffraction pattern of 
NOS G586S mutant crystal. Oscillation range 1.00,  Exposure time 30.0 s; detector 
distance 269.4 mm; resolution at corner 2.5 A; resolution at edge 3.54 A. 
The crystals were found to belong to space group P2 1 2 1 2 1 with cell dimensions a = 
51.9630b = 110.8470c = 164.6270 a=/3=r90. 
Data processing was carried out using MOSFLM (120) and SCALA (121). The 
structure was solved by molecular replacement using PHASER (122) and the wild-
type nNOS0,, structure (PDB entry I 0M4), stripped of water, was used as a starting 
model. Electron density fitting was carried out using the programs TURBO-FRODO 




Chapter 6: Crystallographic Studies on rat G586S nNOS0,, 
6.5 The crystal structure of 6586S nNOS (by C. Bruckmann) 
The dataset corresponding to the structure of G586S nNOS0, was refined to a final 
R-factor of 19.8% (R = 25.3 %; table 6.1) achieving a maximum resolution of 2.59 
A. 
The refined model is composed of two protein molecules each including residues 
from 299 to 716 and one b-type heme. Each subunit contains also one H 413 molecule 
bound in its binding pocket (figure 6.7) and one L-arginine molecule bound in the 
active site. 
Figure 6.7: the 2F0 —Fe electron density map around the 14413. The map is contoured 
at I a. In this figure are also shown some relevant residues binding the cofactor. 
Residues in green belong to the same monomer, while residues in blue belong to the 
other monomer of the dimer. 
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Protein nNOSoxy (G586S) 
Ligand L-Arg 
PDB entry T.B.A. 
Space group P2 1 2 1 2 1 
cell dimensions a = 51.9630 b = 110.8470 c = 
resolution (A) 35.00-2.60 (2.692.60)* 
total no. of reflections 408362 
no. of unique reflections 27819 
completeness (%) 92.7 (70.8)* 
I/[ OVA 13.9 (2.7)* 
Rmerge (%)a 10.0 (24.0)* 
R 0 (%)b 19.87 
Rfr 	(%)C 25.39 
rmsd from ideal values 
bond lengths (A) 0.006 
bond angles (deg) 1.047 
Ramachandran analysis 
most favoured (%) 88.0 
additionally allowed (%) 11.6 
no. of waters included in refinement 196 
Table 6.1: Data collection and refinement statistics * Values in parentheses represent 
statistics for the highest resolution shell a = hl(h) - 11(h)I/ EhIII(h), where 
1 1(h) and 1(h) are the ith and mean measurement of reflection h, respectively. b R0 
= EhIFO - FI/ EhF0, where F. and F c are the observed and calculated structure factor 
amplitudes of reflection h, respectively. C  Rfree is the test reflection data set, 5 % 
selected randomly for cross validation during crystallographic refinement. 
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The electron density around residue 586 (figure 6.8), different from that in the wild 





Figure 6.8: Stereoview of electron density around the heme, serine 586, and L-Arg at 
the active site of G5865 nNOS (monomer A). The electron density map was 
calculated using Fourier coefficients 2 F0 - F, where F 0 and F are the observed and 
calculated structure factors, respectively, the latter based on the final model. The 
contour level is 1.0 , where o is the rms electron density 
As evidenced in the overlay of the monomer of G5865 mutant with the wild-type 
(figure 6.9) the residue substitution in the active site does not have a significant 
effect on the overall structure of the protein. This is confirmed by the rms parameter 
(root-mean-square) which indicates the deviation between the a-carbon backbone of 
each monomer of either G586S and wild type nNOS, (PDB code 1 0M4): this is 
only 0.3 A. 
As shown in figure 6.14, L-arginine maintains the same interactions with the G586S 
enzyme that it has with the wild-type enzyme. However, the distance between the 
guanidinium nitrogen of L-arginine and the side chain oxygen of the 586 serine is 2.9 
A, consistent with the formation of a hydrogen bond. 
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Figure 6.9: Overlay of nNOS0,, wild-type (orange, PDB entry 10M4) and G586S 
mutant (blue). The hemes and the RB are represented as sticks and coloured 
respectively dark red and yellow. The Zn atom at the dimer interface is represented 
as a sphere. The substrates bound at the active site are coloured according to the 
chain colour. 
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Figure 6.10 The active site of the nNOS.. y G586S mutant, showing some of the 
interactions between the bound L-Arg and the active site residues, that are the same 
as observed in the wild-type enzyme structure. The new hydrogen bond between L-
Arg and Ser586 is represented in cyan as a dotted line. 
As discussed in chapter 3, the affinities of NOS OX  wild-type for L-arginine and 
NOHA are very similar (table 3.1), while the G586S mutant displays increased 
affinities for both substrates. The stabilizing effect in the G586S enzyme for L-Arg is 
a factor of 10 greater then in wild-type, while the affinity for NOHA is only doubled 
in the G586S enzyme. 
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As said, this comparison suggests a new capability for L-arginine of forming a 
supplementary hydrogen bond induced by the presence of Ser586. The same 
hydrogen-bond is likely to be formed in the presence of NOHA, which on the other 
hand, has a slightly greater volume due to the additional hydroxyl group: this can 
clash with the oxygen of Ser586 and may negatively affect its binding in the catalytic 
site. 
A model of the active site, built by overlaying NOHA with the L-Arg in the crystal 
structure, can help to visualize and explain substrate specificities and affinities 
(figure 6.11). 
Such a model has been built only for illustrative purposes, and is obviously not 
taking into account the residue motion that can occur upon NOHA binding. The 
crystal structure of nNOS0,, G586S in complex with NOHA would certainly provide 
more information on the NOHA binding affinity. 
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17 
Figure 6.11 Model of nNOS0, in complex with NOHA created by placing the 
NOHA over the bound L-Arg. It is possible to observe that in this model the 
additional hydroxyl group of NOl-JA clashes with the oxygen of Ser586 
The binding orientation of L-arginine in the active site of the G586S mutant enzyme 
is very similar to that observed in the wild-type nNOS 0,,. In the mutant it is 
noticeable that a slight bending of the guanidinium group plane such that the nitrogen 
is hanging directly over the heme-iron and is closer to the metal. Figures 6.12 and 
6.13 show the active sites of the wild-type and the G586S mutant structures with L-
arginine. 
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Figure 6.12 Stereoview of an overlay of the active site region of wild-type nNOS 
(orange) and (1586S mutant (blue) viewed from the top. L-Arg from the G586S 
enzyme (in blue) and L-Arg from the wild-type display the same position in the 
active site. 
le 
Figure 6.13 Stereoview of an overlay of the active site region of wild-type nNOS 
(orange) and G586S nNOS (blue) viewed from the side. 
As already discussed during the kinetic characterization of the nNOS 0,, G586S 
mutant, the accumulation of a novel reaction intermediate has been observed in the 
presence of H4B and substrate, subsequent to oxyferrous species formation. This 
could be due to a stabilizing effect introduced with the G586S mutation. In 
particular, as this effect has been observed only in the presence of substrate, it is 
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possible that it is due to an interaction between the oxy-heme species and substrate 
determined by a different position assumed by the latter. Also, it has been proposed 
that the newly formed interaction with the intermediate observed after the oxyferrous 
compound formation could have the nature of a hydrogen-bond. The shorter distance 
between the guanidinium-nitrogen and the heme-iron observed in the structure 
(figure 6.13) support this hypothesis. 
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7 CONCLUSIONS 
Nitric Oxide Synthases are important as a consequence of the fact that they produce the 
key signalling molecule Nitric oxide: this eclectic factor plays a role in a variety of 
physiological pathways ranging from cytotoxic agent to neurotransmitter and 
vasodilator. The enzymatic reaction with which NO is produced by NOSs is thought to 
follow the general pattern of another heme-protein group, cytochrome P450s, with the 
difference that the complete reaction is performed by NOS in two cycles, which maybe 
possibly similar. Initially the ferrous heme-iron binds molecular oxygen forming the 
oxyferrous species which is activated by one-electron reduction to break the 0-0 bond 
and produce the putative reactive species which perform the oxygen atom insertion, 
compound I. In the first cycle the latter inserts a hydroxyl group at the guanidinium 
terminal of the substrate, L-arginine, forming NOHA. This stays bound in the active site 
and undergoes the second cycle where, through the insertion of an oxygen atom is 
cleaved to form citrulline and NO. The globally accepted version of the reaction has 
been inferred by a series of analyses, but the actual reactive species has never been 
identified. The last accumulating species along the course of the reaction is the 
oxyferrous compound: the events downstream remain unknown due to the high rate at 
which they occur, and the next detected species is the resting ferric enzyme. The aim of 
this PhD project was to contribute to our understanding of the NOS reaction, 
particularly in identifying intermediates that form in the unknown part of the reaction. 
Despite performing very similar reactions to that of P450, NOS has a much higher 
degree of hydrophobicity in its catalytic site. The reason of this difference is unknown, 
and we used it as an inspiration in the attempt to find out the details of the chemical 
mechanism. The idea was to create a nNOS 0,, active site environment with some 
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hydrophilic nature that has the capability to stabilize and allow the accumulation of 
intermediates during the reaction by means of newly formed interactions. A series of 
mutants were then generated replacing hydrophobic amino acids with residues capable 
of forming H-bonds. When tested, not all the mutants were significantly different 
catalytically in comparison with the wild type enzyme. However the mutant where 
glycine 586 was replaced by a senne (G586S nNOS0 ) had unusual properties when the 
decay of the oxyferrous compound was observed in the presence of L-arginine and 1-1413. 
The results suggested that the mutation we engineered was effective in stabilizing at 
least one of the reaction intermediates by means of a newly formed interaction. Further 
catalytic characterization of the mutant reaction, using the enzyme inhibitor amino-R 113, 
proved that formation of the new intermediate relies on the second electron being 
transferred from 1-1 413 to the oxy-ferrous compound: this suggests that the newly 
stabilized intermediate is possibly a species involved in the normal catalytic cycle 
forming downstream from the oxyferrous complex, and results from its activation. 
In order to understand the nature of the newly formed active site interactions, we 
characterized the way the G586S nN0So mutant binds its substrates. Several 
susbtrate-analogues and diatomic ligands that mimic 02 behaviour, such as CO and NO 
were tested. We then compared the results with those characterizing the wild type 
enzyme. We observed a ten-fold higher affinity of the mutant for L-arginine, compared 
to that of the wild type; the stabilizing effect was smaller in the presence of NOHA, due 
possibly to a stenc clash between the new residue and the bulkier ligand. This type of 
behaviour was confirmed by analogue affinity titrations. Through the diatomic ligands 
affinities measurements it was evident that a direct interaction between the mutated 
residue and the heme is to be ruled out. The stabilizing effect induced by the serine 586 
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was exerted only in the presence of the substrate. It is then possible that the ligand 
binding is optimized by a new interaction caused by a repositioning of the substrate. 
Considering the importance of structural data to corroborate these speculations, we 
embarked on the effort to obtain the crystal structure of the mutant in the presence of L-
arginine, and managed to solve the structure at a 2.59 A resolution. This showed that the 
new serine residue is at a suitable distance and orientation to form a hydrogen bond with 
the guanidinium terminal of the substrate. Furthermore, the distance between one of the 
guanidinium nitrogens and the heme iron was shorter, suggesting a better position to 
influence diatomic ligand binding to the heme-iron. Finally we measured the reduction 
potential of the G586S nNOS0, in the presence and absence of L-arginine by 
potentiometric titrations: a comparison with the data relative to the WT enzyme showed 
that the absolute values of the potential and the 10 mV shift caused by the substrate 
binding are consistent with the mutant enzyme conserving the heme native electrical 
properties. 
Understanding the nature of the new interaction gain insight into the mechanism. The 
shorter distance between the heme iron and the guanidinium nitrogen just above it 
shown by the enzyme structure. However, even with the highest possible resolution of 
the structure it wouldn't be possible to incontrovertibly claim that the distance is 
significantly shorter than in the WT enzyme. Nevertheless it is likely that this is the case 
and that the newly formed interaction affects the catalytic behaviour of the enzyme. 
Resolution of the G586S nNOS0,, structure in the presence of either the other substrate, 
NOHA, or of substrate-analogues, would provide further useful information on the 
binding orientation of substrates. 
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Another important issue, in the attempt to understand the stabilizing effect due to the 
mutation, is the protonation state of the serine residue itself. Although the pKa of the 
amino acid in solution (-13) would suggest that the serine is likely to be in its 
protonated form, in the active site framework this may not be the case. The H-bond 
network could favour the stabilization of its unprotonated form: in this case the H-bond 





On the other hand, if the serine is protonated an interaction can be formed between its 
proton and the peptide carbonyl of tryptophan 587, as well as between the serine 
terminal oxygen and one of the substrate guanidinium protons. 
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'2 
The oxyferrous species, after its activation by the second electron transfer, is thought to 
undergo two consecutive protonations in order to form the actual reactive species that 
perform the reaction in both cycles: consequently the easiness with which both protons 
are transferred has an impact on the overall rate and mechanism of the reaction. It has 
been speculated that the source of one or either both protons could be the active site 
bound substrate. The serine 586, if in a protonated state would probably favour at least 
one of the protonation steps by promptly replacing the substrate donated proton. On the 
other hand if the serine is unprotonated, the interaction formed with the guanidinium 
group could be seen as one of a stronger kind if compared with a H-bond: the proton 
between the guanidinium nitrogen and the serine oxygen could bridge the two atoms 
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causing an overall stabilization of the guanidinium proton. This would in turn disfavour 
the transfer of a proton from the substrate to the oxygen-heme intermediate. 
The importance of speculating about the protonation state of the mutated serine is 
related to the different ways this would affect the observed catalytic behaviour, and 
would provide insights about the mechanism with which the new intermediate is 
stabilized and its identity. It is difficult to give an interpretation about the mechanism 
taking place ignoring the identity of the newly detected intermediate. Hence, its 
identification, for example by means of spectroscopic techniques such as EPR, would 
constitute an important step towards completing the puzzle of the mutant reaction 
course. Equally useful would be the analysis of the G586S nNOSOX), catalytic behaviour 
in a range of different pHs, paying attention though to the stability of the enzyme. 
It is also important to know if the newly observed intermediate is part of a normal NOS 
cycle, in particular concerning the production of NO: hence, either by detection of NO 
as a product of the G586S nNOS holo-enzyme reaction by enzymatic assays, or by 
FPLC analysis of the reaction products, proof of the normal enzyme reaction is a key 
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